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The work in incorporated in the thesis with the title "STUDIES ON
HETEROCYCLIC ENTITIES OFMEDICINAL INTEREST" has been described
as under.
[A] STUDIES ON PYRAZOLES
[B] STUDIES ON PYRIDINES
[A] STUDIES ON PYRAZOLES
We are engaged in a programme to explore novel heterocyclic entities
in order to study their pharmacological profile. Our effort are focused on
introduction of chemical diversity in the molecular frame work in order to
synthesizing active molecule of widely different composition.
Pyrazole derivatives have been found to possess a wide range of
therapeutic activities like anticonvulsant, antiinflammatory, antitubercular
CNS depressant, fungicidal, herbicidal, hypnotic, etc.
Prompted by these facts, we have designed and synthesized some new
schiff's base, azetidinone, thiazolidinone, oxadiazole and pyrazolone nucleus.
The study describes in the following parts.
PART - I  : STUDIES ON 2-AZETIDINONES
The β-lactum drugs are still the most prescribed antibiotics used in
medicine. Azetidinone possess a wide spectrum of biological activities such
as antibiotic, antidepressant, sedative, hypnotic, etc. These valid observation
led us to synthesise some novel azetidinone derivatives in search of agent
having better potency which have been described as under.
1
2SECTION - I : Synthesis and therapeutic evaluation of 3-p-
Chlorophenyl-5-substituted benzalhydrazino
carbonyl pyrazoles
Schiff's base of type (I) have been synthesised by the condensation of
3-ρ-chlorophenyl-5-hydrazenocarbonyl pyrazole moiety with various
aromatic aldehydes.
SECTION - II : Synthesis and therapeutic evaluation of 3-p-
Chlorophenyl-5-(2'-aryl-3'-chloro-2-azetidinon-1'-
ylaminocarbonyl) pyrazoles
2-Azetidinone derivatives of type (II) have been synthesised by the
condensation of schiff's base of type (I) with chloroacetyl chloride in presence















Type - (II) R = Aryl
3PART - II : STUDIES ON THIAZOLIDINONES
Compounds bearing thiazolidinone moiety are endowed with a variety
of biological activities such as antimicrobial, CNS depressant, antitubercular,
sedaytive, anticonvulsant, etc. With a view to suppliment these valid
observations it was contemplated to synthesise some 4-thiazolidinone
derivatives which have been described in following sections.
SECTION - I : Synthesis and therapeutic evaluation of 3-p-
Chlorophenyl-5-(2'-aryl-4-thiazolidino-3'-yl)
aminocarbonyl pyrazoles
Thiazolidinone derivatives of type (III) have been synthesised by the
condensation of different schiff's base of type (I) with thioglycolic acid.
PART - III : STUDIES ON 1,3,4-OXADIAZOLES
1,3 ,4-Oxadiazo les  are  assoc ia ted wi th  broad spec t rum of
pharmacological activities like anaesthetic, hypnotics, hypoglycemic,
antifungal, etc. These valid observations prompted us to synthesise
oxadiazole derivatives with better therapeutic value which have been
described as under.









4SECTION - I : Synthesis and therapeutic evaluation of 3-p-
Chlorophenyl-5-(5'-aryl-1',3',4'-oxadiazol-2'-yl)
pyrazoles
The oxadiazole derivatives of type (IV) have been synthesised by the
condensation of 3-ρ-chlorophenyl-5-hydrazinocarbonyl pyrazole with
different aromatic acids in presence of POCl3.
PART - IV : STUDIES ON PYRAZOLONES
Among a wide variety of heterocycles that have been explored for
developing biologically active molecules like pyrazolones have played an
important role in medicinal chemistry. They have been reported to be possess
antimicrobial, anti-HIV, antidiabetic, CNS depressant anticancer etc. These
valid observations prompted us to synthesise some pyrazolone derivatives
which have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 3-p-
Chlorophenyl-5-(3'-methyl-4'-arylhydrazono-5'-
oxo-pyrazol) pyrazoles


















5The pyrazolones of type (V) have been prepared by the condensation
of 3-ρ-chlorophenyl-5-hydrazinocarbonyl pyrazole with different 2-
(substituted phenyl hydrazono) ethyl-2,3-dioxobutyrate.
PART - V: STUDIES ON CHALCONES
Chalcones are phenylstyryl ketone containing reactive ethylinic group
(-CO-CH=CH-). Chalcone derivatives represent various biological activities
such as  ant ibacter ia l ,  analges ic ,  anthe lmint ic ,  ant i in f lammatory,
antitubercular, antifungal, antimicrobial, etc. These valid observation led
us to synthesise some novel chalcone derivatives, which have been
described as under.
SECTION - I : Synthesis and therapeutic evaluation of 1-Aryl-
3 - (1 'N-phenyl -3 ' -β -pyr idy l -4 ' -pyrazoly l ) -2 -
propene-1-ones
The chalcone derivatives of type (VI) have been prepared by the
condensation of 1n-Phenyl-3'-β-pyridyl-4-formyl-pyrazole with different aryl
ketones in presence of 40% NaOH.
PART - VI : STUDIES ON CYANOPYRIDONES
Cynaopyridone derivatives have attracted considerable attention in
view of their great therapeutic importance as antifungal, antibacterial,
antidiabetic and hypertensive agents. To approach these goal, preparation






Type - (VI) R = Aryl
6SECTION - I : Synthesis and therapeutic evaluation of 3-
Cyano-6-aryl -4-(1 'N-phenyl-3 ' -β -pyridyl -4 ' -
pyrazolyl)-1,2-diydropyridin-2-ones
The cyanopyridone derivatives of type (VII) have been prepared by
the condensation of different chalcone of type (VI) with ethyl cyano acetate.
PART - VII : STUDIES ON PYRAZOLINES
Pyrazoline derivatives are endowed with different therapeutic activities
such as  ant ibacter ia l ,  analges ic ,  anthe lmint ic ,  ant i in f lammatory,
antitubercular, etc. These valid observation led us to synthesise some novel
pyrazoline derivatives bearing 1N-phenyl-3-β-pyridyl pyrazole moiety,
which have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 1-Aryl-
5 - ( 1 'N -pheny l - 3 ' - β - p y r i d y l - 4 ' - p y r a zo l y l ) -
pyrazolines













Type - (VIII) R = Aryl
7The pyrazoline derivatives of type (VIII) have undertaken by the
reaction of chalcones of type (VI) with hydrazine hydrate.
SECTION - II : Synthesis and therapeutic evaluation of 1N-
Acetyl-3-aryl -5-(1 'N-phenyl-3 ' -β -pyridyl-4 ' -
pyrazolyl)-pyrazolines
The pyrazoline derivatives of type (IX) have been prepared by the
reaction of chalcones of type (VI) with hydrazine hydrate and glacial acetic
acid.
[B] STUDIES ON PYRIDINES
Pyridine derivatives have a wide range of applications and are found
to possess most effect ive therapeutic activit ies l ike anti tubercular,
antiinflammatory, anthelmintic, antiviral, antihistaminic, etc.
In order to developing compounds with better drug potential, it was
contemplated to synthesise some derivatives like chalcones, pyrimidinones,
thiopyrimidines and aminopyrimidines bearing pyridine nucleus and to study








Type - (IX) R = Aryl
PART - VIII : STUDIES ON PYRIMIDINONES
Pyrimidinone nucleus possess remarkable pharmaceutical importance
and biological activity. Some of the pyrimidinones, which occur as natural
product, like nucleic acids and vitamin B and can be used as therapeutic
agent for the treatment of AIDS and antitumor agents, keeping in association
with pyrimidinones with varied biological activity, it was thought worthwhile
to synthesise new pyrimidinone as under.
SECTION - I : Synthesis and therapeutic evaluation of 3-Aryl-
1-(β-pyridyl)-2-propene-1-ones
The compounds of type (X) have been prepared by the condensation
of 3-acetyl pyridine with different aryl aldehydes in presence of 40% NaOH.
SECTION - II : Synthesis and therapeutic evaluation of 4-Aryl-
6-β-pyridyl,1,2-dihydropyrimidin-2-ones
The pyrimidinone derivatives of type (XI) have been synthesised by





Type - (X) R = Aryl








PART - IX : STUDIES ON THIOPYRIMIDINES
Thiopyrimidine represent one of the most active classes of compounds
possessing wide spectrum of biological activities, such as significant in vitro
activity against DNA and RNA viruses including polio and herper viruses,
diuretic, antitubercular, etc. In view of these facts, it was contemplated to
synthesise thiopyrimidine derivatives which have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 4-Aryl-
6-β-pyridyl-dihydropyrimidin-2-thione
The compounds of  type (XI I )  have been synthes ised by the
condensation of chalcones of different type (X) with thiourea in presence of
HCl as a catalyst.
PART - X: STUDIES ON AMINOPYRIMIDINES
It has been reported that pyrimidine derivatives are associated with
various biological activities like antifungal, antitubercular, antibacterial,
herb ic ida l ,  e tc .  These  va l id  observa t ions  led  us  to  synthes i se
aminopyrimidine derivatives which have been described as under.






Type - (XIII) R = Aryl







The compounds of  type (XII I )  have been synthesised by the
condensation of chalcones of different type (X) with guanidine hydrochloride
in presence of NaOMe as a basic catalyst.
The constitution of the synthesised products have been characterised
using  elemental analyses, infra red and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectroscopy. Purity of all the
compounds have been checked by thin layer chromatography.
In vitro study of multiple biological activities.
(1) All the  compounds have been evaluated for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37 Rv at a concentration of 6.25 µg/ml using Rifampin
as standard drug, which have been tested at Tuberculosis Antimicrobial
Acquisation Coordinating Facility (TAACF), Alabama, U.S.A.
(2) All the compounds have been also evaluated for their antibacterial
activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of
40 µg/ml. The biological activity of the synthesised compounds have






Medicinal chemistry is at the forefront of innovation, blending synthetic
chemistry, molecular modeling, computational biology, structural genomics and
pharmacology to discover and design new drugs, and investigate their interaction
at the molecular, cellular, and whole-animal level.
Medicinal Chemistry is an interdisciplinary research area incorporating
synthetic organic chemistry, biochemistry, pharmacology, molecular biology and
pharmaceutical chemistry in the search for better drugs. The effective treatment
of patients with various diseases such as AIDS and cancer depends, to a great
extent, on the ability of medicinal chemists to discover new drugs. Immune
suppressing medications available today have made possible surgical procedures
such as heart transplants that were unthinkable in a previous generation.
Medicinal chemists have the opportunity to not only  advance the frontier of
science but also to see their work directly contribute to alleviating many of the
diseases affecting mankind. Recent advances in a number of disciplines have
created exciting new opportunities for medicinal chemistry. Synthetic organic
chemistry has progressed over the last several decades to a level where molecules
of great complexity can be effciently constructed.
The word 'drug' is derived from the french word 'drogue' which means a
dry herb. According to 'WHO' a drug may be defined as "Any substance as
product which is used or intended to be used for modifying or exlporing
physiological system or pathological status for the benefit of the recipient".
Medicinal Chemistry is mainly divided in two parts. The first, chemotherapy,
concerns the treatment of infections, parasites or malignant diseases by chemical
agents, usually substances that shows selective toxicity towards the pathogen.
11
The other division relates to diseases of bodily dysfunction and the agents
employed are mainly compounds that effect the functioning of enzymes, the
transmission of nerve impulses or the action of hormones on receptors,
Over six million compounds are recorded in chemical abstracts and
approximately half of these are heterocyclic. They are widely distributed in nature
and are essential to life; they play a vital role in the metabolism of all living
cells. There are a vast number of pharmacologically active heterocyclic
compounds, many of which are in regular clinical use. Some of these are natural
products, for example antibiotics such as penicillin and cephalosporin. However,
the large majority are synthetic heterocycles which have found wide spread
use, for example as anticancer agents, analeptics, analgesics and hypnotics.
The successful application of heterocyclic compounds in these and many
other ways, and their appeal as materials in applied chemistry and  in more
fundamental and theoretical studies, stems from their very complexity; this
ensures a virtually limitless series of structurally novel compounds with a wide
range of physical, chemical and biological properties, spanning a broad spectum
of reactivity and stability.
Most of the alkaloids which are nitrogenous bases occuring in plants and
many antibiotics including penicillin and streptomycin have also heterocyclic
r ing system. Many natural  pigments such as indigo, haemoglobin and
anthocyanin are heterocycles. Most of the sugars and their derivatives including
Vitamin C for instance, exist largely in the form of five membered. Vitamin B6
(pyridoxime) is a derivative of pyridine essential in amino acid metabolism.
Important drugs poisons and medicines (both natural and synthetic) such as
sulphathiazole, pyrethrin, retenmone, strychnine, reserpine, certain of the
antihistaminics, the ergot alkaloids caeffine, cocaine, barbiturates, etc. are
heterocyclic compounds.
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During the period 1940 to 1960 a large number of important drugs have
been introduced and this period is regarded as "Golden Period" of new drug
discovery. These are some of the specific examples representing new therapeutics.
Name of Drug Year
1. Sulpha drugs 1933 The first antibacterial drug
2. Penicillin 1940 Antibiotic
3. Chloroquine 1945 Antimalarial
4. Methyldopa 1950 Antihypertensive
5. Chlorthiazide 1957 Diuretic
6. Adrenergic betablockers 1958 Coronary Vasodilatory
7. Semi synthetic penicillins 1960 Antibacterial
8. Trimethoprim 1965 Antimicrobial
9. Disodium Chromoglycoate 1967 Antiallergic
Aims and Objectives
In the pharmaceutical field, there has always been and will continue to be
a need for new and novel chemical inhibition of biological fraction. Our efforts
are focused on the introduction of chemical diversity in the molecular frame
work in order to synthesizing pharmacologically interesting compounds of widely
different composition.
During the course of research work, looking to the applications of the
heterocyclic compounds, several entities have been designed, generated and
characterized using spectral studies. The details are as under.
v To Generate  severa l  der iva t ives  l ike  azometh ines ,  aze t id inones ,
thiazolidinones, oxadiazoles and pyrazolones, bearing 3-p-chlorophenyl
pyrazol-5-carboxy acid hydrazide.
13
v To synthesise chalcones, simple pyrazolines, acetyl pyrazolines and cyano
pyridones bearing 1N-phenyl-3'-β-pyridyl-4-formyl-pyrazole.
v To generate derivatives l ike oxo-pyrimidines, thiopyrimidines and
aminopyrimidines bearing pyridine.
v To characterise these products for structure elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
v To check the purity of all compounds using thin layer chromatography.
v To evaluate these new products for better drug potential against different
strains of Gram positive and Gram negative bacteria along with fungal
strain Aspergillus niger.
v Selected compounds have been sent to "Tuberculosis Antimicrobial
Acquisition and Co-ordinating Facility" (TAACF), Southern Research






The pyrazole ring system (I) consists of a doubly unsaturated five membered
ring containing two adjacent nitrogen atoms. Knorr1,2 first synthesised a
compound containing this system in 1883 by the reaction of ethylacetoacetate
with phenyl hydrazine which yield 1-phenyl-3-methyl-5-pyrazolone (II).
Knorr3 introduced the name pyrazole for this ring system because this
nucleus was derived from pyrrole by replacement of carbon by nitrogen atom.
In recent years, pyrazole derivatives have gained lots of interest becuse of its
prominent pharmaceutical properties. Many pyrazolone dyes are especially
important in colour photography.
SYNTHETIC ASPECTS
Several methods for the preparation of pyrazoles are narrated in literature.
1. The reaction of hydrazine or its derivatives such as alkyl or aryl hydrazines,
semicarbazide or amino-guinidine with 1,3-dicarbonyl compounds.
2. R.  M.  Sa leh4 have prepared pyrazo le  by cyc l i za t ion of  e thy l -2-

















3. The reaction of hydrazine with α,β-unsaturated carbonyl compounds.
4. The reaction of aliphatic diazo compounds such as diazomethane or diazo
ester with acetylene or olefins.
THERAPEUTIC IMPORTANCE
Several pyrazole derivatives reported to possess pharmacological activity






















































Much research has been carried out with the aim to finding out therapeutic
values of pyrazole moiety since their discovery. A large number of substituted












































E. Akio et. al.19 have synthesised pyrazole derivatives (III) as antitumor
agents. W. Kutsuaki and co-workers20 have prepared pyrazoles and reported
their nimeticidal activity.
R. Y. Huang and co-workers21 have prepared some1,2,4-triaryl-4-alkyl-
pyrazoles as estrogen receptor. C. Vittoria et. al.22 have prepared pyrazoles as
adenosine receptor antagonist. David L. Selwood and co-worker23 have
prepared pyrazole derivatives as activators of the nitric oxide receptor.
Bebbington David et. al.24 have synthesised pyrazoles as protein kinase
inhibitors. Volk Thorsten et. al.25 have prepared pyrazoles and reported their
herbicidal activity. Gellibert and co-worker26 have prepared pyrazole derivatives
and shown them as TGF-B inhibitors. Berta Daniela et. al.27 have synthesised
pyrazoles useful as anticancer, antiproliferative, antiviral and immunosuppressant

























Adnan A. Bekhil et. al.29 have synthesised pyrazoles (VI) and studied their
antiinflammatory and antimicrobial activity. Okada Itara et. al.30 have
synthesised and reported pyrazoles (VII) as agrochemical fungicides.
Dymock et. al.31 have prepared pyrazole derivatives as HIV reverse
transcriptase inhibitors. T. Van Herk et. al.32 have synthesised pyrazole
derivatives and reported as nicotinic acid receptor. Some, pyrazoles are found
to possess anticancer33, herbicidal34-35, 5-HT20 receptor36, neuropeptide T5
receptor antagonist37, COX-II inhibitor38, glycine transporter protein inhibitor39
and antibacterial activities40.
[A] : STUDIES ON PYRAZOLES
PART - I : STUDIES ON 2-AZETIDINONES
PART - II : STUDIES ON 4-THIAZOLIDINONES
PART - III : STUDIES ON 1,3,4-OXADIAZOLES
PART - IV : STUDIES ON PYRAZOLONES
PART - V : STUDIES ON CHALCONES
PART - VI : STUDIES ON CYANOPYRIDONES





























Azetidinones, known41 as β-lactams since 1907, possess four membered
ring system bearing internal amide linkage. The discovery of an azitidin-2-one
ring in penicillin led to development of the compounds bearing this ring system.
Due to powerful activity of penicillin (II)42,43 and clinically more useful
cephaloshporin (III)44 leads to investigate chemistry of azetidinone ring system.
The basic skeleton commonly encountered in β-lactam antibiotics are the penam
(IV) and cepham (V) and high reactivity of β-lactam ring system is responsible
for the antibiotic activity of these compounds.
Much efforts has been put into the synthesis of simpler β-lactam for testing
as antibiotics, antidepressants, sedative44 etc as great interest has been aroused
by their conversion into linear polymers.
SYNTHETIC ASPECT
A review by J. C. Sheehan and E. J. Corey45 reports representative
















( I ) ( II ) ( III )
20Azetidinones...
MECHANISM
Explanation of the formation of β-lactams is given by the following
mechanism52,53. Synthesis of β-lactam of the addition of C-N to C-C=O
component to form a ring substituted acetyl chloride with electron withdrawing
substituents and atleast one hydrogen at carbon add to imines in the presence
of amine bases54. The mechanism take place by non-concerted cycloaddition
reaction as depicted in following scheme (VI).
In many cases by treating a mixture of the imine and dichloroacetic acid
with POCl3
55 or POBr3
56 the reaction may be experimented. The intermediate
formed was the acid chloride through the phosphorus halide participate as an
electrophilic catalyst as shown in following scheme (VII).
The synthesis of β-lactam derivatives can be explained by following
mechanism57,58.
The formation of cis and trans β-lactam take place via (2+2) cyclo addition
involving a ketene and an imine obtained from phenyl glyoxal or phenoxy ketene
and phenyl ethylamine or N-Methylimines. The cis and trans stereochemistry
mainly depends on the substituents attached with ketene part and imine is
believed to exist in more stable E-configuration.
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Azomethine containing nitrogen atom has lone pair of electrons. This
nitrogen nucleophile of azomethine attacks on ketene possessing donor group
such as alkoxy and acceptor group such as thioalkoxy or thioaryloxy, thereby
generates intermediates such as (XI) and (XII). They have three types of different
resonating structures which on cyclisation generates cis β-lactam through less
stable intermediate (VIII) and generates more stable trans β-lactam via more
stable conformation (IX) and (X) stabilised due to sulphur atom.
THERAPEUTIC IMPORTANCE
β-Lactam drugs are sti l l  most widely prescribed antibiotics used in
medicine59. A large number of 3-chloromonocyclic β-lactams have been
prepared by cyclo addition of β-β'-disubstituted enamines with arylisocyanates
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which possess powerful antibacterial activity60. Goto J. et. al.61 have prepared
a series of β-[(2-amino pyrimidyl)-2-oxyiminoacetamido]-cephalsporins as useful
antibiotics.
N-[(Substituted-oxy)-hydroxyphosphinyl]-2-azetidinones62, 4-(trifluoro
methyl)-2-azetidinone63 derivatives were prepared as intermediates for
antibiotics. Several alkyl, alkenyl, alkynol 2-azetidinones64 and 3-alkyl-4-
halomethyl/aryl methyl-2-azetidinones useful as intermediates of antibiotics65
have been reported.
2-Azetidinones of type (XIII) and (XIV) have been found to be active as
hypocholesterolemic agents66 and antiinflammatory67 respectively.
2-Azetidinone derivatives have been reported to possess anticancer68,
cystein protease inhibitor69, antidegenerative70,71, antifungal and antiviral72
activity.
More S. V. and et. al.73 have prepared new azetidinone derivatives (XV)

















( XIII ) ( XIV )
Where, A = Substituted heterocycle,
R
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 = Substituted Phenyl
23Azetidinones...
CONTRIBUTION FROM OUR LABORATORY
H. H. Parekh and co-workers have synthesised 2-azetidinones bearing
dapson derivatives74, thiourea75 and 6-hydroxypyrimidine76 moieties in search
of potent antimicrobial agents. A. R. Parikh and co-workers prepared 2-
azetidinone (XVI) derivative bearing aryl77-79, benzylsulphonamido80, 2-aryl-
1,3,4-thiadiazole81, dapson82 moieties in order to study antimicrobial activity.
General structures for above reference is as under :
CH2
N N






C    R
Cl
Y
X    N
( XVI )
NH –




























H. H. Parekh et. al. have synthesised variety of 2-azetidinones (XVII) bearing
pyrimidinone moiety in search of potent antitubercular agent83.
Recently, Govindarajan R. and et. al.84 have prepared new azitidinone
derivatives (XVIII) and tested for antitubercular activity. Choudhari B. P. et.
al.85 have reported some azetidinones which exhibitis antibacterial activity.
Ghosa l ,  Amina e t .  a l .86 have  synthes i sed new aze t id inone as
hypocholesterolemic agents.
In view of therapeutic activities of 2-azetidinones and pyrazole, in was
contemplated to synthesise some new 2-azetidinones in search of agent
possessing higher biological activity with least side effect which have been
described as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3 - p - C H L O R O P H E N Y L - 5 - S U B S T I T U T E D
BENZALHYDRAZINOCARBONYL PYRAZOLES
SECTION - II : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3-p-CHLOROPHENYL-5-(2'-ARYL-3'-CHLORO-2-
AZETIDINON-1'-YL AMINOCARBONYL) PYRAZOLES


































SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-
CHLOROPHENYL-5-SUBSTITUTED BENZALHYDRAZINOCARBONYL
PYRAZOLES
In view to getting better agent and considering the association of various
biological activity of a large no. of compounds either linear or heterocyclic,
bearing azomethine group have been reported. The preparation of schiff's base
of type (I) have been undertaken by the condensation of 3-p-chlorophenyl-5-
hydrazinocarbonyl pyrazole with different aromatic aldehydes, as shown in
reaction scheme.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in  Part-I Section-I (D). The
ant imycobacter ia l  ac t iv i ty  was  car r ied out  towards  Mycobacter ium






Type - (I) R = Aryl
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REACTION SCHEME













Two drops gla. CH3COOH
EtOH












IR SPECTRAL DATF OF 3-p-CHLOROPHENYL-5-(p-ANISYL) BENZAL HYDRAZINO
CARBONYL PYRAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (sym.) 2835 2863-2843 537
-CH3 C-H i.p.i def. 1456 1470-1435 "
C-H o.o.p. def. 1402 1395-1370 "
Aromatic C-H str. 3051 3080-3030 538
C=C str. 1560 1585-1480 "
C-H i.p. def. 1028 1070-1000 "
C-H o.o.p. def. 815 835-810 "
Ether C-O-C str. 1253 1275-1200 537
Schiff's Base C=N str. 1606 1660-1580 538
Pyrazole N-H str. 3317 3300-3200 "
moety C=O str. 1654 1700-1650 "
C-N str. 1172 1220-1020 537

























































PMR SPECTRAL STUDY OF 3-p-CHLOROPHENYL-5-(p-CHLOROPHENYL)-
BENZALHYDRAZINOCARBONYL PYRAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 7.28 Jba=9.0 2H doublet Ar-Hb,b'
2. 7.51 Jab=9.0 2H " Ar-Ha,a'
3. 7.57 Jde=9.0 2H " Ar-Hd,d'
4. 7.65 Jed=9.0 2H " Ar-He,e,
5. 8.48 - 1H singlet Ar-Hf


































IR SPECTRAL DATA OF 3-p-CHLOROPHENYL-5-SUBSTITUTED BENZALHYDRAZINO
CAROBYL PYRAZOLES


















































































m/z =  200 
m/z =  230 
m/z =  105
m/z =  279
m/z =  191 m/z =  112 m/z =  354
m/z =  3
m/z =  382
m/z =  148
m/z =  240
m/z =  214
m/z =  417  (m + 1)
ANTIMICROBIAL ACTIVITY
Method : Cup-Plate87
Gram positive bacteria : Staphylococcus aureus
Bacillus megaterium
Gram negative bacteria : Proteus vulgaris
Escherichia coli
Fungi : Aspergillus niger
Concentration : 40 µg
Solvent : Dimethyl formamide
Standard drug : Ampicillin, Amoxicillin,  Norfloxacin,
Penicillin, Greseofulvin
The antimicrobial activity was compared with standard drugs viz. ampicillin,
amoxicillin, norfloxacin, penicillin and greseofulvin. The zones of inhibition have
been measured in mm.
Antitubercular activity
The antitubercular evaluation of the compounds was carried out at
Tuberculous Antimicrobial Acquisition and Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric System
Bacteria : Mycobacterium tuberculosis H37 Rv
Concentration : 6.25 µg/ml
Standard drug : Rifampin
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-
CHLOROPHENYL-5-SUBSTITUTED BENZALHYDRAZINOCARBONYL
PYRAZOLES
[A] Synthesis of Ethyl 2-(p-chlorophenyl) pyruvate88
A mixture of p-chloroacetophonone (1.55 g, 0.01 M) and diethyl oxalate
(1.45 g, 0.01 M) in 50 ml sodium methoxide solution (0.005 g atom sodium/ 25
ml methanol) was warmed for 5 min., cooled and the separated solid washed
with dil. HCl and recrystalized from rectified spirit to give ethyl 2-(p-chlorophenyl)
pyruvate. Yield 85%; m.p. 129oC. (Anal calcd. for C12H11O4Cl Found: C, 56.48;
H, 4.28%; Required : C, 56.60; H, 4.35%; ).
[B] Synthesis of 3-p-Chlorophenyl-5-hydrazinocarbonyl pyrazole88
A solution of ethyl 2-(p-chlorophenyl) pyruvate (2.38 g, 0.01 M) and
hydrazine hydrate (1 g, 0.02 M) in ethanol (50 ml) was refluxed for 6 hrs. and
cooled. The solid thus separated, was crystallized from rectified spirit to give 3-
p-chlorophenyl-5-hydrazinocarbonyl pyrazole. Yield 50%; m.p. 103oC. (Anal
calcd. for C10H9N4OCl Found: C, 50.63; H, 3.74; N, 23.58; Required : C,
50.75; H, 3.83; N, 23.67%).
[C] Synthesis of 3-p-Chlorophenyl-5-(ρ-chlorophenyl) benzalhydrazino
carbonyl pyrazole
A mixture of 3-p-chlorophenyl-5-hydrazinocarbonyl pyrazole (2.36 g, 0.01
M) and 4-chlorobenzaldehyde (1.4 g, 0.01 M) was refluxed in methanol for 6
hrs. and poured onto crushed ice, the product isolated was crystallised from
ethanol. Yield 60%; m.p. 170oC. (Anal calcd. for C17H12N4OCl2 Found: C,
56.70; H, 3.48; N, 15.45; Required : C, 56.82; H, 3.34; N, 15.59%).
TLC solvent system: Hexane : Ethyl acetate (8 : 2)
Similarly other schiff's base have been prepared. The physical data are
recorded in Table No. 1.
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(D) Therapeutic evaluation of 3-p-Chlorophenyl-5-substituted
benzalhydrazinocarbonyl pyrazoles
All the products have been evaluated for antimicrobial activity as described
under.
(A) Antimicrobial activity
It was carried out by cup-plate diffusion method which has been described
as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The
nutrient agar broth prepared by the usual method, was inoculated aseptically
with 0.5 ml of 24 hrs. old subcultures of B. megaterium, S. aureus, E. coli,
P. vulgaris in separate conical flasks at 40-50oC and mixed well by gently
shaking.  About 25 ml content of the flask were poured and evenly spreaded in
a petridish (13 cm in diameter) and allowed to set for 2 hrs. The cups (10 mm in
diameter) were formed by the help of borer in agar medium and filled with 0.04
(40 µg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also
maintained with 0.04 mol of DMF in a similar manner and the zones of inhibition
of the bacterial growth were measured in millimeter and recorded in Graphical
Chart No. 1.
(II) Antifungal activity
A. niger was employed for antifungal activity using cup-plate method. The
culture was maintained on Sabouraud's agar medium was inoculated with 72
hrs. old 0.5 ml suspension of fungal spores in a separate flask. About 25 ml of
the inoculated medium was evently spreaded in a petridish and allowed to set
for two hrs. The cups (10 mm in diameter) were punched. The plates were
incubated at 30oC for 48 hrs. After the completion of incubation period, the
zones of inhibition of growth in the form of diameter in mm was measured.
Along the test solution in each petridish one cup was filled up with solvent
35
which act as control. The zones of inhibition are recorded in Graphical Chart
No. 1.
(III) Antitubercular activity
The antitubercular evaluation of the compounds were carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordinating Facility (TAACF), USA.
Primary screening of the compounds for antitubercular activity have been
conducted at 6.25 µg/ml towards Mycobacterium Tuberculosis H37Rv in
BACTEC 12 B medium using 460 radiometric system. The compounds
demonstrating atleast >90% inhibition in the primary screen have been retested
at lower concentration towards Mycobacterium Tuberculosis H37Rv to
determine the actual minimum inhibitory concentration (MIC) in the BACTEC
460.
The antitubercular activity data have been compared with standard drug
Rifampin at 0.25 µg/ml concentration and which showed 98% inhibition. The























1a C6H5- C17H13N4OCl 324.5 220 0.612 41 17.25 17.11
1b 4-OCH3-C6H4- C18H15N4O2Cl 354.5 238 0.548 36 15.79 15.61
1c 3,4-(OCH3)2-C6H3- C19H17N4O3Cl 384.5 277 0.710 51 14.56 15.42
1d 4-OH-3-OCH3-C6H3- C18H15N4O3Cl 370.5 242 0.578 50 15.11 15.01
1e 2-OH-C6H4- C17H13N4O2Cl 340.5 171 0.728 51 16.44 16.30
1f 4-OH-C6H4- C17H13N4O2Cl 340.5 164 0.778 51 16.44 16.31
1g 2-NO2-C6H4- C17H12N5O3Cl 369.5 250 0.624 47 18.94 18.80
1h 3-NO2-C6H4- C17H12N4O3Cl 369.5 261 0.770 42 18.94 18.81
1i 2-Cl-C6H4- C17H12N4OCl2 359 191 0.615 51 15.60 15.46
1j 4-Cl-C6H4- C17H12N4OCl2 359 170 0.648 60 15.60 15.45
1k -CH=CH-C6H5- C19H15N4OCl 350.5 202 0.690 48 15.97 15.85
1l 3-OC6H5-C6H4- C23H17N4O2Cl 416.5 278 0.748 41 13.44 13.30
1m α-C4H3O- C15H11N4O2Cl 314.5 118 0.699 47 17.80 17.65
1n C14H9-(9-Anthraldehyde) C25H17N4OCl 424.5 225 0.604 42 13.19 13.03

































B. mega 20 14 17 20 15 17 12 13 22 19 11 20 18 14 22 24 2
S. aureus 14 19 12 19 20 12 16 20 13 16 17 11 16 18 20 22 1
E. coli 19 16 13 20 14 16 14 12 19 11 12 18 14 16 19 18 2
P. vulgaris 15 17 12 16 15 14 11 19 14 17 15 15 12 17 17 20 2
A.niger 19 17 18 21 14 14 18 19 13 17 19 13 19 17 0 0 0





TABLE NO.1a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain Inhib
162308 Rbp-10 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 85  ''
162307 Rbp-9 C6H5-CH=CH- Sau.uni Alamar H37Rv >6.25 72  ''
162311 Rbp-13 8-Cl-C9H5N- Sau.uni Alamar H37Rv >6.25 63  ''
162309 Rbp-11 2-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 58  ''
162312 Rbp-14 3-OCH3-8-Cl-C9H4N- Sau.uni Alamar H37Rv >6.25 52  ''
162300 Rbp-2 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 51  ''
162305 Rbp-7 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 41  ''
162310 Rbp-12 3-OC6H5-C6H4- Sau.uni Alamar H37Rv >6.25 35  ''
162304 Rbp-6 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 16  ''
162299 Rbp-1 C6H5- Sau.uni Alamar H37Rv >6.25 12
162306 Rbp-8 4-OH-3-OCH3-C6H3- Sau.uni Alamar H37Rv >6.25 8  ''
162301 Rbp-3 2-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 7  ''
162302 Rbp-4 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 3  ''
162313 Rbp-15 2-C4H3O- Sau.uni Alamar H37Rv >6.25 0  ''
162303 Rbp-5 C14H9- Sau.uni Alamar H37Rv >6.25 0  ''
NIAID/ Southern Research institute/ GWL Hansen's Center/
Colorado state university proprietary information.
MIC Ri fampin
= 0.25µg/ml









SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-
CHLOROPHENYL-5-(2 ' -ARYL-3' -CHLORO-2-AZETIDINON-1' -YL
AMINOCARBONYL) PYRAZOLES
Looking to the interesting antibiotic activity of monocyclic β-lactams, it
was considered worthwhile to synthesise compounds bearing ethopobate moiety
linked to β-lactam nucleus. 2-Azetidinones of type (II) have been prepared by
the condensation of schiff's bases of type (I) with chloroacetyl chloride in presence
of triethylamine as a basic catalyst, as shown in reaction scheme.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared


















IR SPECTRAL DATA OF 3-p-CHLOROPHENYL-5-(2'-(p-ANISYL)-3'-CHLORO-2-
AZETIDINON-1'-YL AMINOCARBONYL) PYRAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2956 2975-2950 537
-CH3 C-H str. (sym.) 2854 2880-2860 "
C-H i.p. def. 1452 1470-1435 "
Aromatic C-H str. 3060 3080-3030 538
C=C str. 1556 1585-1480 "
C-H i.p. def. 1033 1125-1000 "
C-H o.o.p. def. 812 835-810 "
Azetidinone C=O str. 1705 1470-1650 540
ring C-Cl str. 783 830-560 539
Ether C-O-C str. 1226 1275-1200 537
Pyrazole N-H str. (sym.) 3226 3200-3300 538
moiety C=O str. 1660 1700-1650 "
C=N str. 1620 1640-1580 537


















































PMR SPECTRAL STUDY OF 3-p-CHLOROPHENYL-5-[2'-(3,4-DIMETHOXYPHENYL)-
3'-CHLORO-2-AZETIDINON-1'-YL AMINOCARBONYL]PYRAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.85 - 3H singlet Ar-OCH3
2. 3.88 - 3H " Ar-OCH3
3. 6.74 Jgh=9.6 1H doublet -CHg
4. 7.09 Jba=9.0 2H " Ar-Hb,b'
5. 7.19 Jab=9.0 2H " Ar-Ha,a'
6. 7.36 Jef=9.0 1H d. doublet Ar-He
Jed=3.0
7. 7.41 Jde=3.0 1H doublet Ar-Hd
8. 7.52 Jfe=9.0 1H " Ar-Hf
9. 8.11 Jhg=9.6 1H " -CHh



















2a C6H5 1704 1666
2b 4-OCH3-C6H4 1705 1660
2c 3,4-(OCH3)2-C6H3 1709 1665
2d 4-OH-3-OCH3-C6H3 1714 1668
2e 2-OH-C6H4 1716 1670
2f 4-OH-C6H4 1713 1665
. 2g 2-NO2-C6H4 1702 1670
2h 3-NO2-C6H4 1704 1669
2i 2-Cl-C6H4 1712 1666
2j 4-Cl-C6H4 1713 1665
2k α-CH=CH-C6H5 1708 1668
2l 3-OC6H5-C6H4 1697 1669
2m α-C4H3O 1707 1671




IR SPECTRAL DATA OF 3-p-CHLOROPHENYL-5- (2 ' -ARYL-3 ' -CHLORO-2-
AZETIDINON-1'-YL-AMINOCARBONYL)PYRAZOLES
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
C=O str.
(Pyrazole Moiety)





































































































m/z =  391
BASE PEAK
m/z =  342
m/z =  106
m/z =  148
m/z =  280
m/z =  335
m/z =  204 m/z =  270
m/z =  328
m
m/z =  137m/z =  122
m/z =  238m/z =  167
m/z =  214
NH
EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-
CHLOROPHENYL-5-(2 ' -ARYL-3' -CHLORO-2-AZETIDINON-1' -YL
AMINOCARBONYL) PYRAZOLES
[A] Synthesis of 3-p-Chlorophenyl-5-hydrazinocarbonyl pyrazole
See Part - I, Section - I(B).
[B] Synthesis of 3-p-Chlorophenyl-5-substituted benzalhydrazino
carbonyl pyrazole
See Part - I, Section - I(C).
[C] Synthesis of 3-p-Chlorophenyl-5-[2'-(3,4-dimethoxyphenyl)-3'-
chloro-4'-oxo-azetidin-1'-yl aminocarbonyl] pyrazoles
A solution of 3-p-chlorophenyl-5-(3,4-dimethoxyphenyl) benzalhydrazino
carbonyl pyrazole (3.84 g, 0.01 M) in dry dioxane (50 ml) was added to a well
stirred mixture of chloroacetyl chloride (0.95 ml, 0.012 M) and triethyl amine
(1.08 ml, 0.02 M) as a basic catalyst at 0oC. The reaction mixture was then
stirred for 18-20 hrs. and kept for 3 days at room temperature. The product
isolated was recrystallised from methanol. Yield 65%; m.p. 168oC. (Anal calcd.
for C21H18N4O4Cl2 Found: C, 54.81; H, 3.98; N, 12.04; Required : C, 54.66;
H, 3.90; N, 12.14%).
TLC solvent system: Acetone ; Benzene (6 : 4)
Similarly other 2-azetidinones have been prepared. The physical data are
recorded in Table No. 2.
(D) Therapeutic evaluation of 3-p-Chlorophenyl-5-(2'-aryl-3'-chloro-2-
azetidinon-1'-yl aminocarbonyl) pyrazoles
Antimicrobial testing was carried out as described in Part - I, Section -























2a C6H5- C19H14N4O2Cl2 401 197 0.712 51 13.96 13.80
2b 4-OCH3-C6H4- C20H16N4O3Cl2 431 159 0.691 47 12.99 12.81
2c 3,4-(OCH3)2-C6H3- C21H18N4O4Cl2 461 168 0.610 65 12.14 12.04
2d 4-OH-3-OCH3-C6H3- C20H18N4O4Cl2 447 119 0.690 48 12.53 12.38
2e 2-OH-C6H4- C19H14N4O3Cl2 417 134 0.739 55 13.43 13.27
2f 4-OH-C6H4 C19H14N4O3Cl2 417 141 0.748 49 13.43 13.28
2g 2-NO2-C6H4- C19H13N5O4Cl2 446 215 0.590 54 15.69 15.51
2h 3-NO2-C6H4- C19H13N4O4Cl2 446 229 0.548 64 15.69 15.48
2i 2-Cl-C6H4- C19H13N4O2Cl3 435.5 102 0.502 68 12.86 12.76
2j 4-Cl-C6H4- C19H13N4O2Cl3 435.5 112 0.611 41 12.86 12.75
2k -CH=CH-C6H4- C21H16N4O2Cl2 427 278 0.678 47 13.11 13.01
2l 3-OC6H5-C6H4- C25H18N4O3Cl2
493 261 0.677 54 11.36 11.24
2m α-C4H3O- C17H12N4O3Cl2 391 78 0.551 44 14.32 14.22
2n C14H9-(9-Anthraldehyde) C27H18N4O2Cl2 501 291 0.509 51 11.17 11.05

































B. mega 17 14 17 20 21 13 18 12 19 13 16 18 13 18 22 24 23
S. aureus 20 13 17 12 16 13 16 19 21 14 12 16 16 16 20 22 19
E. coli 18 15 17 11 19 12 13 20 12 17 14 19 17 16 19 18 20
P. vulgaris 17 15 12 19 18 13 11 14 19 13 14 13 15 14 17 20 21
A.niger 13 17 19 18 21 17 15 19 20 17 13 19 18 19 0 0 0









4-Thiazolidinones are derivatives of thiazolidine with a carbonyl group at
4-position (I). The cyclic structure was assigned after the recognition of mercapto
acetic acid as the primary product of hydrolysis of 3-phenyl-2-phenylamino-4-
thiazolidinone89.
Actithiazic acid (II), a well known antibiotic, isolated from a species of
streptomyces shown specific in vitro activity against M. tuberculosis, but it is in
active against in vivo probably due to antagonisation by biotin, bears the 4-
th iazo l id inone ske le ton90.  The deep s tudy o f  "The Chemis t r y  o f  4-
thiazolidinones" was done in 1962 by Brown91 and in 1977 by Newkome and
Nayak4.
SYNTHETIC ASPECT
Synthesis of 4-thiazolidinones has been reported either by cyclisation of
acyclic compounds or by interconversion among appropriately substituted
thioazol idinone derivat ives.  Several  method for the preparat ion of 4-
thiazolidinones are naratted in literature93,94. Synthesis of 4-thiazolidinones
has been reported by the microwave irradiation95-97.
MECHANISM
The reaction of 4-thiazolidinones proceeds by the attack of mercaptoacetic
acid upon the >C=N- group, with the addition of -S-CH2-COOH to the carbon










In this reaction, the uncyclised intermediate is formed. In several cases the
uncyclised product has been isolated98. Phosphorous pentoxide in dioxane was
used for subsequent cyclisation of certain uncyclised product99. In may instances
4-thiazolidinones can conveniently be prepared by refluxing the mixture of
thioglycolic acid and schiff's base in benzene1002, dry ether101 or ethanol102.
The nucleophilic attack of mercaptoacetic acid anion on carbon of
azomethine, which has got positive character while nitrogen has negative
character is evidenced103.
THERAPEUTIC IMPORTANCE
4-Thiazolidinone derivatives substituted at 2- and 3- positions are associated
with diverse biological activities. The frequent occurence of the group-NH-C-
NH or its tautomer in compounds possess in vitro tuberculostatic activity.104


































12. Plant Growth Inhibitor118
13. H1-Histamine antagonists119
Orlinskii, M. M.120 have synthesised some new 4-thiazolidinones (IV) as
antioxidant and antischistosomal agent. Vigoria M. G. et. al.121 have synthesised
4-thiazolidinones and studied their antiinflammatory and analgesic activity.
Matiychuk, V. S. et. al.122 have synthesised 4-thiazolidinones (VI) as
hypoglycemic agents.
CONTRIBUTION FROM OUR LABORATORY
H. H. Parekh and co-workers have synthesised 4-thiazolidinones (VII)
bearing dapson123,124, s-tr iazine125,126, acridin-9-yl127, thymoloxy
acetamido128, 6-hydroxypyrimidine129 moieties and reported as antimicrobial
agent.
Parikh et. al. have synthesised variety of 4-thiazolidinone derivatives
bearing diphenyl sulphone130,131 substituted aryl132-135, arsanilic acid136,
2-aryl-1,3,4,-thiadiazole137, substituted quinoline138, γ-picolinylamino139, s-






































moieties and reported as potent antimicrobial agent.
General structure for above reference is as under.
Moreover  A.  J .  Baxi  e t .  a l .143 have synthes ised some novel  4-
thiazolidinones which shows antiHIV, antitumor and antihypertensive activities.
Recently A. R. Parikh et. al.144 have synthesised 4-thiazolidinones bearing
quinoline moiety (VIII) and reported as potent antibacterial agents.
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Y = H,CH3 CH2 COOH; Z = H,CH3,C6H5 ; R = Aryl
52Thiazolidinones...
Pfahl, Magnus et. al.145 have prepared new 4-thiazolidinone (IX) derivative
and tested for anticancer activity. Govindarajan R. et. al.146 have reported 4-
thiazolidinones (X) which exhibits antitubercular, antifungal and antibacterial
activity. Martin et. al. 147 have synthesised some new 4-thiazolidinones (XI) as
nuclear receptors with therapeutic uses.
In persuing the work on the 4-thiazolidinone derivatives incorporating
pharmaceutically active moloecules, the novel 4-thiazolidinone derivatives have
been described as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3 - p - C H L O R O P H E N Y L - 5 - ( 2 ' - A R Y L - 4 -






































SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-
C H LO R O P H E N Y L - 5 - ( 2 ' - A R Y L - 4 -T H I A Z O L I D I N O N - 3 ' -Y L )
AMINOCARBONYL PYRAZOLES
4-Thiazolidinone have been found to be associated with diverse biological
activities. These finding prompted us to synthesise some representative of 4-
thiazolidinone derivative of type (III). Cyclocondensation of schiff's base of type
(I) with mercapto acetic acid, as shown in reaction scheme.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared



















IR SPECTRAL DATA OF 3-p-CHLOROPHENYL-5-(2'-(p-ANISYL)-4-THIAZOLIDINO-
3'-YL) AMINOCARBONYL PYRAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2927 2975-2950 537
-CH3 C-H str. (sym.) 2802 2880-2860 "
C-H i.p. def. 1487 1470-1435 "
C-H o.o.p. def. 1363 1395-1370 "
-CH2 C-H def. 1419 1485-1445 "
Aromatic C-H str. 3051 3080-3030 538
C=C str. 1533 1585-1480 "
C-H i.p. def. 1093 1125-1000 "
C-H o.o.p. def. 837 835-810 "
Ether C-O-C str. 1261 1275-1200 537
Thiazolidinone C=O str. 1714 1760-1655 "
ring C-S-C str. 665 700-600 539
Pyrazole N-H str. 3354 3300-3200 537
moiety C=O str. 1683 1700-1650 "
C=N str. 1606 1660-1580 538
C-N str. 1153 1220-1020 "


























































PMR SPECTRAL STUDY OF 3-p-CHLOROPHENYL-5-[2'-(p-CHLOROPHENYL)-4-
THIAZOLIDINO-3'-YL]-AMINOCARBONYL PYRAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 4.17 - 2H singlet -COCH2
(Thiazolidine)
2. 6.91 Jba=9.0 2H doublet Ar-Hb,b'
3. 7.38 Jab=9.0 2H " Ar-Ha,a'
4. 7.47 Jed=9.0 2H " Ar-He,e'
5. 7.50 - 1H singlet Ar-Hf
6. 7.57 Jde=9.0 2H doublet Ar-Hd,d'
7. 7.58 - 1H singlet Ar-Hc


















3a C6H5 1714 1680
3b 4-OCH3-C6H4 1714 1683
3c 3,4-(OCH3)2-C6H3 1691 1666
3d 4-OH-3-OCH3-C6H3 1684 1662
3e 2-OH-C6H4 1695 1668
3f 4-OH-C6H4 1708 1678
. 3g 2-NO2-C6H4 1687 1662
3h 3-NO2-C6H4 1689 1660
3i 2-Cl-C6H4 1701 1688
3j 4-Cl-C6H4 1689 1681
3k α-CH=CH-C6H5 1709 1685
3l 3-OC6H5-C6H4 1718 1691
3m α-C4H3O 1699 1670




IR SPECTRAL DATA OF 3-p-CHLOROPHENYL-5-(2'-ARYL-4-THIAZOLIDINO-3'-YL)
AMINOCARBONYL PYRAZOLES
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
C=O str.
(Pyrazole Moiety)

























SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-
C H LO R O P H E N Y L - 5 - ( 2 ' - A R Y L - 4 -T H I A Z O L I D I N O N - 3 ' -Y L )
AMINOCARBONYL PYRAZOLES
[A] Synthesis of 3-p-Chlorophenyl-5-hydrazinocarbonyl pyrazoles
See Part - I, Section - I(B).
[B] Synthesis of 3-p-Chlorophenyl-5-substituted benzalhydrazino
carbonyl pyrazoles
See Part - I, Section - I(C).
[C] Synthesis  o f  3-p-Chlorophenyl -5- [2 ' - (p -chlorophenyl - ) -4 -
thiazolidino-3'-yl] aminocarbonyl pyrazoles
3-p-Chlorophenyl-5-(p-chlorophenyl) benzalhydrazinocarbonyl pyrazole
(3.58 g, 0.01 M) was fused with mercapto acetic acid (0.925g, 0.01 M) and
refluxed for 10hrs. at 120oC. The reaction mixture was cooled and triturated
with 10% sodium bicarbonate solution and crystallised from ethanol. Yield 25%;
m.p. 192oC. (Anal calcd. for C19H14N4O2Cl2S Found: C, 52.45; H, 3.41; N,
12.75; Required : C, 52.65; H, 3.23; N, 12.93%).
TLC solvent system: Acetone ; Benzene (8 : 2)
Similarly other schiff's base of type (I) were condensed with mercapto acetic
acid. The physical data are recorded in Table No. 3.
(D) Therapeut ic  evaluat ion of  3-p-Chlorophenyl -5- (2 ' -ar y l -4-
thiazolidino-3'-yl) aminocarbonyl pyrazoles
Antimicrobial testing was carried out as described in Part - I, Section -























3a C6H5- C19H15N4O2ClS 398.5 108 0.611 38 14.05 13.96
3b 4-OCH3-C6H4- C20H17N4O3ClS 428.5 171 0.690 42 13.06 12.92
3c 3,4-(OCH3)2-C6H3- C21H19N4O4ClS 458.5 158 0.628 37 12.21 12.04
3d 4-OH-3-OCH3-C6H3- C20H17N4O4ClS 444.5 144 0.710 50 12.59 12.48
3e 2-OH-C6H4- C19H15N4O3ClS 414.5 179 0.591 31 13.50 13.31
3f 4-OH-C6H4- C19H15N4O3ClS 414.5 202 0.747 32 13.50 13.32
3g 2-NO2-C6H4- C19H14N5O4ClS 443.5 258 0.667 46 15.78 15.61
3h 3-NO2-C6H4- C19H14N5O4ClS 443.5 292 0.512 38 15.78 15.65
3i 2-Cl-C6H4- C19H14N4O2Cl2S 433 205 0.738 42 12.93 12.81
3j 4-Cl-C6H4- C19H14N4O2Cl2S 433 192 0.690 25 12.93 12.75
3k -CH=CH-C6H4- C21H17N4O2ClS 424.5 209 0.510 39 13.19 13.03
3l 3-OC6H5-C6H4- C25H19N4O3ClS 490 98 0.709 41 11.41 11.30
3m α-C4H3O- C17H13N4O3ClS 388 104 0.519 44 14.41 14.31
3n C14H9-(9-Anthraldehyde) C27H19N4O2ClS 498 278 0.578 45 11.23 11.10

































B. mega 19 16 17 15 19 12 11 12 20 17 14 15 11 18 22 24 23
S. aureus 11 18 14 16 14 17 11 13 19 14 12 17 13 16 20 22 19
E. coli 16 15 14 16 13 15 12 13 17 12 15 15 18 14 19 18 20
P. vulgaris 14 16 14 17 11 12 15 14 18 12 13 14 15 12 17 20 21
A.niger 14 19 15 18 14 16 18 14 20 12 19 14 15 19 0 0 0









Thermally stable neutral aromatic 1,3,4-oxadiazoles148 have been known
for about 80 years. They have been subject to intensive investigation particularly
in the last decade because of their broad spectrum of uses as biologically active
compounds in medicine, agriculture and dyestuff industries. 1,3,4-Oxadiazoles
also have been useful in diverse areas like drug synthesis, heat resistant and UV
absorbing polymers. The literature prior to 1965 is surveyed in comprehensive
reviews149-152.
SYNTHETIC ASPECTS
The synthesis of 1,3,4-oxadiazoles is generally carried out using acyclic
precursors and reactions are mainly 'one-bond' or 'two-bond' cyclisation. A
variety of synthetic methods have been reported153-155.
THERAPEUTIC IMPORTANCE
2,5-Disubstituted 1,3,4-oxadiazole derivatives have been tested for various
pharmacological properties, which have been summerised in following sections :
1. Antitubercular156,157
2. Antimalarial158















2-Amino-1,3,4-oxadiazoles act as muscle relaxant172 and showed
antimicotic activity173. Beriger Ernst174 have synthesised a series of oxadiazoles
bearing substituted furan ring system and reported them as nematocides. A
var ie ty  of  oxadiazo les  have been synthes ised and assessed for  the i r
antiinflammatory175 activity. Eduardo Cortes et. al.176 have synthesised some
5-methyl-4H-1-(p-R1-phenyl)-3a, (p-R2-phenyl)-3a, 4-dihydro [1,2,4] oxadiazolo
[4,5-a] [1,5] benzodiazepines to confirm its pharmacological activity as an
anticonvulsant drug (II).
Moreover B. Shivarama Holla et. al.177 have also synthesised 1,3,4-
oxadiazole derivatives (III) and tested for antibacterial activity.
Sulabh Sharma and co-worker178 have reported the antiinflammatory





















J. C. S. Kataky179 have reported 2-amino-[4-(5-(2-chlorophenyl)-1,3,4-
oxadiazol)-2-yl]6-aryl/substituted aryl-7-oxo-6,7-dihydro thiazolo [4,5-d]
pyr imidine-5(H)- thiones and evaluated for  ant imicrobia l  act iv i ty  and
fungitoxicity. Harendra Singh et. al.180 have synthesised 2-aryl-6-arylamino-
1,2,4-thiadiazolo [3,2-b]-1,3,4-oxadiazoles and screened for fungal toxicity.
CONTRIBUTION FROM OUR LABORATORY
Parikh et. al. have synthesised variety181 of 1,3,4-oxadiazoles bearing aryl
sulphonamido aryl182,183, mercapto184, quinolinyl185 and amino moieties
at 2-position (y) and 4'-pyridyl, benzene sulfonamidophenyl, diiodoquinolinoxy
and aryl sulphonamidophenyl at 5-position (X) as antimicrobial agents.
H. H. Parekh and co-workers have investigated 1,3,4-oxadiazoles having
tr iaz ine186,187, phenyl  sulphonyl188, 2 ' - isopropyl-5-methyl  phenoxy
methyl189-191, dapson192-194 moieties at 5-position (X) and aryl, arylamino,
arylsulphonamido, substituted benzalamino moieties at 2-position (y) and
evaluated their antimicrobial activity.



















Y =NH–SO2–R,    Aryl,   –SH,   –NH2,  –NHCO – R,  –N = CH – R
64Oxadiazoles...
More recently H. Parekh et. al.195-1977 have formulated some new
oxadizole derivatives as biologically active agents. K. Mogilaiah198 have
converted N-aroyl-N'-(2-phenyl-1,8-napthridine-3-carbonyl) hydrazine into 3-
(5-aryl-1,3,4-oxadiazol-2-yl)-2-phenyl-1,8-napthridines and the compounds were
screened for their antibacterial activity against the bacteria Escherichia coli,
Pseudomonas aeruginosa, Bacillus subtilis and Bacillus mycoids following
the filter paper disc technique at 400 and 600 µg/disc concentrations.
Chan, Wai Ngor and et. al.199 have synthesised 1,3,4-oxadiazole
derivatives (VI) and reported as orexin receptor antagonists. Grover et. al.200
have synthesised 1,3,4- oxadiazole derivatives and tested for antibacterial
activity. Khan and Akhtar201 have reported the antiinflammatory activity of
some new 1,3,4-oxadiazole derivatives. Ayscough and co-workers202 have
synthesised oxadiazoles (VII) and tested for antiinflammatory activity.
Vital contribution of 1,3,4-oxadiazole ring system to the medicinal chemistry
as an active constituent of antibiotics made chemists to explore for its other
derivatives as therapeutic agents. Accordingly, several derivatives of 1,3,4-
oxadiazoles have been designed as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF





















SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-
CHLOROPHENYL-5-(5'-ARYL-1',3',4'-OXADIAZOL-2'-YL) PYRAZOLES
Synthesis of 1,3,4-oxadiazole derivatives has attracted considerable
attention in view of therapeutic applications. Looking to this, the synthesis of
1,3,4-oxadiazoles of type (IV) was undertaken by the condensation of different
aromatic acid with 3-ρ-chlorophenyl-5-hydrazinocarbonyl pyrazole in presence
of phosphorous oxychloride as shown in reaction scheme.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in  Part-I Section-I (D).














IR SPECTRAL DATA OF 3-p-CHLOROPHENYL-5-[5'-PHENYL-1',3',4'-OXADIAZOL-
2'-YL]PYRAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (sym.) 2837 2863-2843 537
-CH3 C-H i.p. def. 1442 1470-1435 "
C-H o.o.p. def. 1377 1395-1370 "
Aromatic C-H str. 3049 3080-3030 538
C=C str. 1537 1585-1480 "
C-H i.p. def. 1055 1070-1000 "
C-H o.o.p. def. 825 835-810 "
Oxadiazole N-N str. 1026 1050-1010 538
C=N str. 1602 1660-1580 "
C-O-C str. 1245 1275-1200 537
Pyrazole N-H str. 3250 3300-3200 "
moiety C-N str. 1149 1220-1020 538



















































PMR SPECTRAL STUDY OF 3-p-CHLOROPHENYL-5-[5'-(3-METHOXYPHENYL)-
1',3',4'-OXADIAZOLO-2'-YL]-PYRAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.64 - 3H singlet Ar-OCH3
2. 6.64 Jba=9.0 2H doublet Ar-Hb,b'
3. 7.30 Jab=9.0 2H " Ar-Ha,a'
Jbb=1.8
4. 7.64 Jfe=8.1 1H triplet Ar-Hf
Jfg=7.9
5. 6.22 Jgf=7.5 1H doublet Ar-Hg
6. 6.29 Jef=7.9 1H d. doublet Ar-He
Jed=1.8
7. 6.56 - 1H singlet Ar-Hc































SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-
CHLOROPHENYL-5-(5'-ARYL-1',3',4'-OXADIAZOL-2'-YL) PYRAZOLES
[A] Synthesis of 3-p-Chlorophenyl-5-hydrazinocarbonyl pyrazole
See Part - I, Section - I(B).
[B] Synthesis of 3-p-Chlorophenyl-5-(5'-(m-methoxyphenyl)-1',3',4'-
oxadiazol-2'-yl) pyrazole
A mixture of 3-p-chlorophenyl-5-hydrazinocarbonyl pyrazole (2.34 gm, 0.01
M) and 3-methoxy benzoic acid (1.52gm, 0.01M) in phosphorous oxychloride
(5 ml) was refluxed for 5-6 hrs. The contents were cooled and poured onto
crushed ice. It was neutralised with sodium bicarbonate solution and resulting
solid was filtered, dried and crystallised from ethanol. Yield 50%; m.p. 142oC.
(Anal calcd. for C18H13ClN4O2 Found: C, 64.31; H, 3.81; N, 16.50; Required
: C, 64.19; H, 3.86; N, 16.64%).
TLC solvent system: Acetone ; Benzene (3 : 7)
Similarly other substituted oxadiazoles have been prepared. The physical
data are recorded in Table No. 4.
(C) Therapeutic evaluation of 3-p-Chlorophenyl-5-(5'-aryl-1',3',4'-
oxadiazol-2'-yl) pyrazoles
Antimicrobial testing was carried out as described in Part - I, Section -
I(D). The zone of inhibition of the test solutions are recorded in Chart No. 4.























4a C6H5- C17H11N4OCl 322.5 158 0.617 48 17.36 17.22
4b 3-OCH3-C6H4- C18H13N4O2Cl 352.5 142 0.710 50 16.64 16.50
4c 4-OCH3-C6H4- C18H13N4O2Cl 352.5 133 0.60 64 15.88 15.71
4d 2-OH-C6H4- C17H11N4O2Cl 338.5 180 0.548 58 16.54 16.39
4e 4-OH-C6H4- C17H11N4O2Cl 338.5 197 0.690 68 16.54 16.38
4f 2,4-(OH)2-C6H3- C17H11N4O3Cl 354.5 >270 0.671 70 15.79 15.62
4g 2-Cl-C6H4- C17H10N4OCl2 357 241 0.731 61 15.69 15.61
4h 3,4-(Cl)2-C6H3- C17H9N4OCl3 391.5 230 0.644 67 15.69 15.60
4i -CH=CH-C6H5- C19H13N4OCl 348.5 208 0.712 59 16.06 15.89
4j 4-NH2-C6H4- C17H12N5OCl 337.5 181 0.568 80 20.73 20.57
4k 2-NO2-C6H4- C17H10N5O3Cl 367.5 223 0.512 65 19.04 18.86
4l α-C5H4N- C16H10N5OCl 323.5 261 0.529 69 21.63 21.48

































B. mega 17 19 15 14 22 12 16 18 20 16 19 13 22 24 23
S. aureus 18 16 14 13 20 16 18 14 21 12 15 17 20 22 19
E. coli 17 16 14 15 18 12 17 15 18 13 12 16 19 18 20
P. vulgaris 16 14 15 18 13 15 13 18 12 12 17 14 17 20 21
A.niger 16 19 17 17 20 15 18 18 20 15 13 14 0 0 0





TABLE NO.4a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain Inhib
162321 Rbp-23 4-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 67  ''
162323 Rbp-25 2-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 56  ''
162326 Rbp-28 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 43  ''
162319 Rbp-21 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 36  ''
162317 Rbp-19 2,4-(OH)2-C6H3- Sau.uni Alamar H37Rv >6.25 35  ''
162314 Rbp-16 C6H5-Ch=Ch- Sau.uni Alamar H37Rv >6.25 23
162320 Rbp-22 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 18  ''
162318 Rbp-20 3,5-(OH)2-C6H3- Sau.uni Alamar H37Rv >6.25 16  ''
162325 Rbp-27 4-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 12  ''
162324 Rbp-26 3-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 9  ''
162316 Rbp-18 2-OCOCH3C6H4- Sau.uni Alamar H37Rv >6.25 1  ''
162315 Rbp-17 3-C5H4N- Sau.uni Alamar H37Rv >6.25 0  ''
162327 Rbp-29 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
NIAID/ Southern Research institute/ GWL Hansen's Center/
Colorado state university proprietary information.
MIC Ri fampin
= 0.25µg/ml














5-Pyrazolone is a five membered heterocycle having two nitrogen atoms
at the 1 and 2 positions with carbonyl group at the 5-position.  The discovery of
the 1-phenyl-2,3-dimethyl-4-N,N-dimethylamino-5-pyrazolinone dates back to
the year 1908 when V. Farbwake et. al.203 have synthesised the derivative.
C. W. Alstetten204 has also prepared similar derivative in 1922 by the action of
formaldehyde and formic acid with 1-phenyl-2,3-dimethyl-4-amino-5-
pyrazolinone.
SYNTHETIC ASPECTS
Different methods are reported in literature for the preparation of 5-
pyrazolones are as under.
1. By the reaction of 4,4-dibromo-1,3-substituted-pyrazolin-5-ones with 1-
alkyl/aryl-2,4-dithiobiurets205.
2. By the reaction of ethyl acetoacetate with aroyl hydrazines206.
3. By the reaction of ethyl acetoacetate with hydrazine hydrate207.
4. By the reaction of ethyl acetoacetate with aryl hydrazine208.
MECHANISM












Pyrazolone derivatives exhibit broad spectrum of therapeutic activities. The






























































Takashima Y. et. al.221 have synthesised some pyrazolone derivatives
showing herbicidal activity. Akahane A. et. al.222 have synthesised pyrazolone
derivatives which were found to be active against ischemic heart disease such
as angina, diabetes and melancholia. Rajeev Jain et. al.223 have prepared
pyrazolone derivatives (I) and reported as potent antimicrobial agent.
Nakamura K. et. al.224 have synthesised some pyrazolone derivatives and
found to be Cox-11 inhibiting agents useful for the treatment and prevention of
inflammatory conditions, collagen diseases, antiimmune disease, thrombosis,
cancer or neurodegenerative diseases.
Yoshikuni et. al.225 and Bratusek et. al.226 have synthesised 3-methyl-5-
oxopyrazole derivatives of type (II) and (III) respectively.
S. D. Bhardwaj et. al.227 have found anticancer and anti-HIV activity.





































Banks B. J. et. al.229 have prepared pyrazolone derivatives which were active
as antiparasitic agents.
Some co-workers have prepared pyrazolones and tested them for their
herbicidal and insecticidal230, leukotriene inhibitors231, thromboembotic
disorders232, antinflammatory and antimicrobial
233
, coagulation factor234,
anticancer235,236, antiinfective237, antibiotic238, antiinflammatory239,
ant imicrob ia l240,  organ t ransp lanta t ion241,  therapeut ic  agent242,
antithrombotic agent243, inhibitors of (GSK - 3, Aurora-2 and CDK-2)244 activity
and also use for treatment of cardiac disorder245.
Salman, A. S. S.246 have prepared some novel pyrazolone derivatives
(IV) which showed antimicrobial activity. Sharma V. and Khan, M. S. Y.247
have synthesised pyrazolone derivatives (V) which were found to be active as
non-steroidal antiinflammatory drug.
Thus significant biological properties associated with pyrazolones have
aroused considerable interest to design the compounds in which therapeutically
active pyrazole nucleus is incorporated with a view to obtaining compounds
with better drug potential and to study their pharmacological profile, which
have been described as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3 - p - C H L O R O P H E N Y L - 5 - ( 3 ' - M E T H Y L - 4 ' -




























SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-
CHLOROPHENYL-5-(3 ' -METHYL-4' -ARYLHYDRAZONO-5' -OXO-
PYRAZOL-1'-YL CARBONYL) PYRAZOLES
Current interest in the pyrazolone derivatives contemplated us to focus on
the synthesis of 3-p-chlorophenyl-5-(3'-methyl-4'-arylhydrazono-5'-oxo-pyrazol-
1'-lyl carbonyl) pyrazoles of type (V) which has been synthesised by the
condensation of the 3-p-chlorophenyl-5-hydrazinocarbonyl pyrazole with
different 2-(Substituted phenylhydrazino)-ethyl-2,3-dioxybutyrate.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in  Part-I Section-I (D).




















IR SPECTRAL STUDY OF 3-p -CHLOROPHENYL-5- (3 ' -METHYL-4 ' -p -
ANISYLHYDRAZONO-5'-OXO-PYRAZOL-1'-YL CARBONYL) PYRAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2854 2880-280 537
-CH3 C-H i. p. def. 1473 1470-1435 "
C-H def. 1371 1385-1370 "
Aromatic C-H str. 3037 3080-3030 "
C=C str. 1492 1520-1480 538
C-H i.p. def. 1008 1070-1000 "
C-H o.o.p. def. 821 835-810 "
Pyrazolone C=O str. 1703 1760-1655 537
ring C=N 1616 1660-1580 538
N-H str. 975 1050-1000 "
Ether C-O-C str. 1205 1275-1200 537
Pyrazole C=O str. 1668 1700-1650 "
moiety C=N str. 1616 1660-1580 538
C-N str. 1093 1220-1020 "





















































PMR SPECTRAL STUDY OF 3 -p-CHLOROPHENYL-5- (3 ' -METHYL-4 ' -2 -
CHLOROPHENYLHYDRAZONO-5'-OXO-PYRAZOL-1'-YL CARBONYL)PYRAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1. 2.51 - 3H singlet Ar-CH3
2. 7.15 Jef=7.7 1H triplet Ar-He
Jed=7.7
3. 7.25 Jba=9.0 2H doublet Ar-Hb,b'
4. 7.35 Jfe=8.0 1H multiplet Ar-Hf
Jfg=7.2
5. 7.52 Jde=7.9 1H doublet Ar-Hd
6. 7.58 Jab=8.3 2H " Ar-Ha,a'
7. 7.65 Jgf=7.9 1H " Ar-Hg




















5a C6H5 1698 1668
5b 2-OCH3-C6H4 1697 1670
5c 3-OCH3-C6H 1697 1668
5d 4-OCH3-C6H4 1703 1668
5e 2-Cl-C6H4 1702 1670
5f 3-Cl-C6H4 1703 1668
. 5g 4-Cl-C6H4 1705 1670
5h 3-NO2-C6H4 1698 1665
5i 4-NO2-C6H4 1697 1666
5j 3-Cl-4-F-C6H3 1692 1670
5k 3,4-(Cl)2-C6H3 1695 1668
5l 4-F-C6H4 1692 1664
5m 2-CH3-C6H4- 1698 1666




IR SPECTRAL DATA OF 3-p-CHLOROPHENYL-5-(3'-METHYL-4'-ARYLHYDRAZONO-
5'-OXO-PYRAZOLE-1'-YL CARBONYL) PYRAZOLES
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
C=O str.
(Pyrazole Moiety)










































































































m/z =  174
m/z =  260
m/z =  378
m/z =  108
m/z =  150
m/z =
m/z =  246
m/z =  220
m/z =  218
m/z =  437  (m + 1)
EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-
CHLOROPHENYL-5-(3 ' -METHYL-4' -ARYLHYDRAZONO-5' -OXO-
PYRAZOL-1'-YL CARBONYL) PYRAZOLES
[A] Synthesis of 3-p-Chlorophenyl-5-hydrazinocarbonyl pyrazole
See Part - I, Section - I(B).
[B] Synthesis of 2-(o-Chlorophenylhydrazino)-ethyl-2,3-dioxobutyrate
o-Chloro aniline (1.27 g, 0.01 M) was dissolved in a mixture of concentrated
HCl (5 ml) and water (5 ml) and cooled to 0-5oC in ice salt bath, cold aqueous
solution of sodium nitrite (0.69 g, 0.01 M) in water (8 ml) was added dropwise
and diazonium salt so formed was filtered into cold mixture of ethylacetoacetate
(1.28 ml, 0.01 M) and sodium acetate (8 g) in ethanol (25 ml). The resulting
solid was filtered and washed with water and crystallised from ethanol. Yield 65
%; m.p. 135oC.
[C] Synthesis of 3-p-Chlorophenyl-5-(3'-methyl-4'-(o-chlorophenyl
hydrazono)-5'-oxo-pyrazol-1'-lyl carbonyl) pyrazole
A mixture of 2-(o-chlorophenylhydrazino)-ethyl-2,3-dioxo-butyrate (2.68
g, 0.01 M) and 3-p-chlorophenyl-5-hydrazinocarbonyl pyrazole (2.36 g, 0.01
M) in glacial acetic acid were refluxed for 5 hrs. and allowed it to cool overnight.
The resulting solid was filtered and crystallised from ethanol. Yield 70 %; m.p.
152oC. (Anal calcd. for C20H14N6O2Cl2 Found: C, 54.31; H, 3.28; N, 18.98;
Required : C, 54.42; H, 3.17; N, 19.04%).
TLC solvent system: Hexane : Ethylacetate (7 : 3)
Similarly other pyrazolones have been prepared. The physical data are
recorded in Table No. 5.
(D) Therapeutic evaluation of 3-p-Chlorophenyl-5-(3'-methyl-4'-
arylhydrazono-5'-oxo-pyrazol-1'-lyl carbonyl) pyrazoles
Antimicrobial testing was carried out as described in Part - I, Section -























5a C6H5- C20H15N6O2Cl 406.5 168 0.712 61 20.66 20.51
5b 2-OCH3-C6H4- C21H17N6O3Cl 436.5 141 0.610 60 19.24 19.08
5c 3-OCH3-C6H4- C21H17N6O3Cl 436.5 149 0.631 54 19.24 19.09
5d 4-OCH3-C6H4- C21H17N6O3Cl 436.5 132 0.628 53 19.24 19.08
5e 2-Cl-C6H4- C20H14N6O2Cl2 441 152 0.548 70 19.04 18.98
5f 3-Cl-C6H4- C20H14N6O2Cl2 441 164 0.595 74 19.04 18.90
5g 4-Cl-C6H4- C20H14N6O2Cl2 441 159 0.637 78 19.04 18.91
5h 3-NO2-C6H4- C20H14N7O4Cl 451.5 269 0.559 72 20.70 20.54
5i 4-NO2-C6H4- C20H14N7O4Cl 451.5 281 0.708 77 20.70 20.55
5j 3-Cl-4-F-C6H3- C20H13N6O2Cl2F 459 218 0.549 70 18.30 18.15
5k 3,4-(Cl)2-C6H3- C20H13N6O2Cl3 475.5 190 0.670 79 17.67 17.53
5l 4-F-C6H4- C20H14N6O2ClF 424.5 202 0.648 71 19.78 19.62
5m 2-CH3-C6H4- C21H17N6O2Cl 420.5 170 0.602 69 19.97 19.82
5n 4-COOH-C6H4- C21H15N6O4Cl 450.5 118 0.631 68 18.64 18.49

































B. mega 17 19 16 21 15 12 16 20 15 17 19 12 11 14 22 24 23
S. aureus 12 15 16 18 20 17 15 21 18 14 15 17 12 13 20 22 19
E. coli 17 13 16 12 18 11 15 16 14 13 12 14 15 18 19 18 20
P. vulgaris 16 16 14 11 13 14 12 19 14 14 15 14 17 14 17 20 21
A.niger 15 16 18 14 19 14 13 20 17 15 14 16 19 16 0 0 0









The chemistry of chalcones has generated intensive scientific studies
throughout the world, specially interesting are their biological and industrial
appl icat ions. They are known as benzalacetophenones or benzyl idene
acetophenones. Kostanecki and Tambor248 gave the name "Chalcones".
Chalcones are characterised by their possession of a structure in which
two aromatic rings A and B are linked by an aliphatic three carbon chain.
The alternative names given to chalcones are phenyl styryl ketones,
benzalacetophenone, β-phenyl acrylphenone, γ-oxo-α, γ-diphenyl, α-propylene
and α-phenyl-β-benzoethylene.
SYNTHETIC ASPECTS
A considerable variety of methods are available for the synthesis of
chalcones. The most convenient methods is the one that involves the Claisen-
Schmidt condensation of equimolar quantities of a aryl methyl ketones with
aryl aldehyde in the presence of alcoholic alkali249.
Several condensing agents used are alkali of different strength250,
anhydrous aluminium chloride251, boron trif luoride252, aq. solution of
borax253, amino acids254, hydrogen chloride255, phosphorous oxychloride256,






Chalcone formation proceeds through aldol type of condensation and the
process is catalysed by the presence of alkali259. Following are the steps of the
reaction mechanism.
The intermediate aldol type of products formed readily undergoes
dehydration even under mild condition, particularly when R and R' are aryl
groups.
THERAPEUTIC INTEREST
Chalcones are potential biocides, some naturally occuring antibiotics and





















(iii) R' – C+         +    –CH
2
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(v) R' – C – CH
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Moreover, synthesis and antibacterial activity of substituted chalcone
derivatives has been reported by Modil et. al.275 and V. Mudaliar276, Attia A.
et. al.277 have prepared phenoxy chalcones and observed their insecticidal
activity. De Vincenzo et. al.278 have reported chalcone derivatives for their
antiinflammatory activity. Kammei et. al.279 and Han et. al.280 have synthesised
chalcone derivatives having antitumor and antiinflammatory activity respectively.
Ant i feedant  act iv i ty  of  chalcones have been obser ved by Sarma and
Sreenivasulu4281.
Tsotitus and co-workers282 have reported chalcone derivatives for their
antifungal activity. Ezio et. al.283 have demonstrated that chalcones possess a
valuable antiproliferation activity both on sensitive cancereous cell and on cell
which are resistant to common chemotherapeutic drugs some of the chalcones
have been patented for their use for treatment of glueoma284 and showed
ant i funga l285,  a ldose  reduc tase  inh ib i tors286,  ant i cancer287 and
antimicrobial288,289activities. Aldose reductase inhibitor activity of chalcone
derivatives has been reported by Okuyama et. al.290.
Archana, Virendrakishor Srivastava and et. al.291 have synthesised
chalcone derivatives (II) having anticonvulsant activity. Lin, Yah-Meei and co-
workers292 have prepared some chalcone derivatives having anti-tuberculosis
activity.
89Chalcones...
Dimmock J. R and et. al.293 have synthesised some chalcone derivatives
(III) having cytotoxic activity. Lawrence and et. al.294 have prepared some
chalcone combretastain A4 derivatives (IV) having antineoplastic activity.
Wu, Jiu-Hong and co-workers295 have prepared chalcone derivatives
having anti-HIV activity. A potent matrix metalloproteinuse inhibitors chalcone
derivatives (V) has been prepared by Kim, Min-Young and et. al.296. Ni, Liming
and co-workers297 have synthesised chalcone derivatives (VI) used for the

















































Chalcone belong a very good synthon, variety of novel heterocycles with
good pharmacological profile can be designed. These valid observations led us
to explore chalcone chemistry by synthesis ing several  derivat ives l ike
cyanopyridines and pyrazolines bearing different heterocyclic ring systems for
medicinal value, in order to achieving better therapeutic agents, this study is
described as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF




SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-(1'N-
PHENYL-3'-β-PYRIDYL-4'-PYRAZOLYL)-2-PROPENE-1-ONES
Recently, much interest has been focused on the synthesis and biodynamic
behaviour of chalcones and it is a good synthon for various heterocyclic rings.
With a view to obtaining compounds having better therapeutic activity, we have
synthesised 1-aryl-3-(1'N-phenyl-3'-β-pyridyl-4'-pyrazolyl)-2-propene-1-ones by
the condensation of 1N-phenyl-3-β-pyridyl-4-formyl pyrazole with various
atomatic ketones.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared

















Two -three drops alcoholic


















Type - (VI) R = Aryl
93
IR SPECTRAL STUDY OF 1(p-TOLYL)-3-(1'N-PHENYL-3'-β-PYRIDYL-4'-PYRAZOLYL)-
2-PROPENE-1-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2923 2962-2853 537
-CH3 C-H str. (sym.) 2852 2880-2860 "
C-H i.p. def. 1423 1470-1435 "
C-H o.o.p. def. 1369 1395-1370 ''
Aromatic C-H str. 3062 3090-3030 538
C=C str. 1481 1520-1480 "
C-H i.p.def. 1010 1070-810 "
C-H o.o.p. def. 825 835-810 "
Chalcone C=O str. 1658 1760-1655 539
Pyrazole C=N str. 1604 1640-1580 538
moety C-N str. 1170 1220-1020 "
















































PMR SPECTRAL STUDY OF 1- (p -TOLYL)-3- (1 'N-PHENYL-3 ' -β -PYRIDYL-4 ' -
PYRAZOLYL)-2-PROPENE-1-ONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1. 2.42 - 3H singlet Ar-CH3
2. 7.28 Jef=9.0 2H doublet Ar-He,e'
3. 744 - 5H multiplet Ar-Hj,k,l,m,n
4. 7.80 - 1H triplet Ar-Hc
5. 7.81 Jhg=18.0 1H doublet Vin-Hh
6. 7.84 Jgh=18.0 1H " Vin-Hg
7. 7.88 Jfe=6.0 2H " Ar-Hf,f'
8. 8.01 Jbc=9.0 1H d. doublet Ar-Hb
Jba=3.0
9. 8.39 - 1H singlet Ar-Hl
10. 8.69 Jdc=9.0 1H d.doublet Ar-Hd
Jda=2.0




































IR SPECTRAL DATA OF 1-ARYL-3-(1'N-PHENYL-3'-β-PYRIDYL-4'-PYRAZOLYL)-2-
PROPENE-1-ONES















SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-(1'N-
PHENYL-3'-β-PYRIDYL-4'-PYRAZOLYL)-2-PROPENE-1-ONES
[A] Synthesis of N-Aminophenyl-α-methyl-α-(β-pyridyl) azomethine298
A mixture phenylhydrazine (1.08 g, 0.01 M) and 3-acetylpyridine (1.2 g,
0.01 M) in absolute ethanol was refluxed in water bath for 12 hrs. in presence
of 1 ml glacial acetic acid. The crude product was crystallised from absolute
alcohol.  Yield 85%; m.p. 108oC. (Anal calcd. for C13H13N3Cl Found: C, 73.81;
H, 6.11; N, 19.78%; Required : C, 73.91; H, 6.20; N, 19.89%).
[B] Synthesis of 1-Phenyl-3-(β-pyridyl)-4-formyl pyrazole
A compound N-aminophenyl-α-methyl-α-(β-pyridyl) azomethine (0.844 g,
0.004 M) was added in mixture of Vilsmeier-Haack reagent (prepared by dropwise
addition of 1.2 ml POCl3 in ice cooled 10 ml DMF) and refluxed for 5 hrs. The
reaction mixture was poured into ice followed by neutralization using sodium
bicarbonate, crude product was isolated and crystallised from ethanol. Yield
80%; m.p. 154oC. (Anal calcd. for C15H11N3O Found: C, 72.16; H, 4.34; N,
16.73; Required : C, 72.28; H, 4.45; N, 16.86%).
[C] Synthesis of 1-(p-tolyl)-3-(1'N-phenyl-3'-β-pyridyl-4'-pyrazolyl)-2-
propene-1-ones
To a well stirred solution of 1-phenyl-3-(β-pyridyl)-4-formyl pyrazole (2.49
g, 0.01 M) and ρ-methylacetophenone (1.2 g, 0.01 M) in ethanol (25 ml), 40%
NaOH was added till the solution was basic. The reaction mixture was stirred
for 24 hrs. The contents were poured into ice, acidified, filtered and crystallised
from ethanol. Yield 75%; m.p. 128oC. (Anal calcd. for C24H19N3O Found: C,
71.99; H, 4.68; N, 10.42; Required : C, 72.09; H, 4.54; N, 10.51%).
TLC solvent system: Acetone : Benzene (1 : 9)
Similarly other substituted chalcones have been prepared. The physical
data are recorded in Table No. 6.
[D] Therapeutic evaluation of 1-Aryl-3-(1'N-phenyl-3'-β-pyridyl-4'-
pyrazolyl)-2-propene-1-ones
Antimicrobial testing was carried out as described in Part - I, Section - I(D).























6a C6H5- C23H17N3O 351 140 0.612 81 11.96 11.79
6b 4-F-C6H4- C23H16N3OF 369 162 0.648 79 11.38 11.21
6c 4-Cl-C6H4- C23H16N3OCl 385.5 198 0.669 88 10.89 10.70
6d 4-NH2-C6H4- C23H18N4O 366 181 0.712 74 15.29 15.11
6e 4-NO2-C6H4- C23H16N4O3 396 234 0.502 85 14.13 14.01
6f 3-NO2-C6H4- C23H16N4O3 396 248 0.518 89 14.13 13.99
6g 4-OH-C6H4- C23H17N3O2 367 102 0.748 79 11.44 11.28
6h 2-OH-C6H4- C23H17N3O2 367 118 0.579 82 11.44 11.25
6i 4-OCH3-C6H4
- C24H19N3O2 381 142 0.694 70 11.02 10.82
6j 4-CH3-C6H4
- C24H19N3O 365 128 0.611 75 10.51 10.42
6k 4-Br-C6H4- C23H16N3OBr 430 142 0.658 68 9.77 9.62
6l C5H4N- C22H16N4O 352 159 0.681 90 15.90 15.76


































B. mega 12 14 17 17 13 16 13 16 19 17 14 15 22 24 23
S. aureus 15 11 12 15 20 14 18 19 17 16 13 12 20 22 19
E. coli 16 14 11 12 18 14 16 13 15 17 13 13 19 18 20
P. vulgaris 14 17 16 16 15 13 15 17 11 14 12 14 17 20 21
A.niger 18 15 17 20 14 18 16 20 21 17 14 14 0 0 0























( II ) ( III ) ( IV )
INTRODUCTION
Pyridones, which belong to an important group of heterocyclic compounds
have been extensively explored for their applications in the field of medicine.
Pyridones, with a carbonyl group at position 2 (I) have been subject of extensive
study in recent past. Numerous reports have appeared in the literature which
highlight their chemistry and use.
2-Pyridones are derivatives of pyrimidine with carbonyl group at 2-position
(I). Some 2-pyridones are physiologically as well as pharmacologically important
which are as under : eg. amrinone (II), ciclopirox (III) and methylprylon (IV).
Synthetic pyridone derivatives contribute much to the searchable literature
of pyridone derivatives in huge libraries owing to their wide applicability in
different fields.
SYNTHETIC ASPECTS
Different methods for the preparation of 2-pyridones are as follows :
1. K. Folkers and S. A Harris299 have synthesised 3-cyano-2-pyridone by





2. M. A. Sluyter and co-worker300 have prepared fused 2-pyridones.
3. G. Simchen and G. Entemmann301 have synthesised 2-pyridone in which
the ring nitrogen comes from a nitrile group in acyclic precursor.
THERAPEUTIC IMPORTANCE
Pyridone derivatives have been found to possess variety of therapeutic
activities as shown below :
1. Anticancer302
2. Herbicidal303





F. Peter and co-workers312 have prepared pyridinylmethyl substituted
pyridines and pyridones as angiotensin II antagonist. H. Posnes313 synthesised
2-pyridones and 2-pyrones as physiologically active compounds. Mukhtar
Hussain Khan and co-workers314,315 have prepared 2-pyridone derivatives




































M. K. Morishita et. al.316 have synthesised m-(2-oxo-1,2-dihydropyridyl)
urea derivatives (VII) possessing cholesterol acyltransterase (ACAT) inhibitory
activity and are useful for the treatment of hyperlipidemia and arteriosclerosis.
I.J. Collins et. al.317 prepared heteroaryl pyridones as GABA α2/α3 ligands.
Pednecker318 synthesised fused 2-pyridone derivatives (VIII), (IX) and (X) as
useful heterocyclic moieties as they possess a broad spectrum of biological
activities such as antiviral, CNS depressant, bactericidal and ulcer inhibitor.
Moreover, several co-workers have prepared 2-pyridones as S3 site of
thrombin inh ib i tor319,  herb ic ida l320,  SH2 domain inh ib i tor
321,
antimicrobial322, GABA-receptor323 and antiinflammatory324.
Upadhyay and co-workers325 have synthesised cyanopyridine derivatives
which showed antifungal and antileishmanial activities. E. Amer326 prepared
3-cyano-2-pyridone derivatives (XI) displaying high antimicrobial activity. Abou


































( IX ) R = Aryl
103Cyanopyridones...
M. G. Nizamuddin et. al.328 have prepared cyanopyridone derivatives (XIII)
and documented their antifungal activity. Tanaka Akira et. al. 329 have prepared
pyrazolo pyridone derivatives. (XIV) Moreover, several co-workers have prepared
2-pyr idones as  nuclear  receptors ,  inc luding l iver  x receptor  330 and
antiinflammatry 331.
Looking to the interesting properties of pyridones, we have synthesised
some new pyridone derivatives, which have been described as under :










































SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-CYANO-6-ARYL-
4-(1'N-PHENYL-3'-β-PYRIDYL-4'-PYRAZOLYL-1,2-DIHYDROPYRIDIN-
2-ONES
Pyridone derivatives have remarkable therapeutic activity. Taking this into
consideration, we have undertaken the preparation of pyridone derivatives.
Hence, the synthesis of 2-pyridone derivatives of type (VII) has been undertaken
by the condensation of chalcones of type (VI) with etyhlcyanoacetate in presence
of ammonium acetate as shown in reaction scheme.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared

















IR SPECTRAL STUDY OF 3-CYANO-6-(p-TOLYL)-4-(1'N-PHENYL-3'-β-PYRIDYL-4'-
PYRAOLYL)-1,2-DIHYDROPYRIDIN-2-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2925 2962-853 537
-CH3 C-H str. (sym.) 2835 2880-2860 "
C-H i.p. def. 1442 1470-1435 "
C-H o.o.p. def. 1371 1395-1370 "
Aromatic C-H str. 3060 3080-3030 538
C=C str. 1506 1585-1480 "
C-H i.p.def. 1028 1070-1000 "
C-H o.o.p. def. 831 835-810 "
Pyridone C=N str. 2196 2240-2120 538
N-H str. 3348 3300-3200 537
N-H def. 1604 1650-1580 "
C=O str. 1712 1760-1655 "
Pyrazole C=N str. 1637 1650-1680 538
moiety C=C str. 1546 1540-1440 "














































PMR SPECTRAL STUDY OF 3-CYANO-6-(p-TOLYL)-4-(1'N-PHENYL-3'-β-PYRIDYL-4'-
PYRAZOLYL)-1,2-DIHYDROPYRIDIN-2-ONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1. 2.37 - 3H singlet Ar-CH3
2. 6.72 - 1H " Ar-Hm
3. 7.22 Jab=8.0 2H doublet Ar-Ha,a'
4. 7.35 - 2H multiplet Ar-Hk,e
5. 7.51 - 4H " Ar-Hc,d,f,g
6. 7.97 Jba=8.0 2H doublet Ar-Hb,b,
7. 7.99 - 1H singlet Ar-Hh
8. 8.62 - 1H d. doublet Ar-Hj
9. 8.79 - 1H doublet Ar-Hl





















7a C6H5 1712 2196
7b 4-F-C6H4 1715 2208
7c 4-Cl-C6H4 1711 2000
7d 4-NH2-C6H4 1712 2220
7e 4-NO2-C6H4 1708 2191
7f 3-NO2-C6H4 1708 2212
. 7g 4-OH-C6H4 1718 2200
7h 4-OCH3-C6H4 1710 2218
7i 4-CH3-C6H4 1716 2220
7j 4-Br-C6H4 1718 2205




IR SPECTRAL DATA OF 3-CYANO-6-ARYL-4-(1'N-PHENYL-3'-β -PYRIDYL-4'-
PYRAZOLYL)-1,2-DIHYDRO PYRIDIN-2-ONES
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
C=N str.
(Cyanopyrdone)




















SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-CYANO-6-ARYL-
4-(1'N-PHENYL-3'-β-PYRIDYL-4'-PYRAZOLYL-1,2-DIHYDROPYRIDIN-
2-ONES
[A] Synthesis of N-Aminophenyl-α-methyl-α-(β-pyridyl) azomethine
See Part - V, Section - I(A).
[B] Synthesis of 1-Phenyl-3-(β-pyridyl)-4-formyl pyrazole
See Part - V, Section - I(B).
[C] Synthesis of 1-(p-Tolyl)-3-(1'N-phenyl-3'-β-pyridyl-4'-pyrazolyl)-2-
propene-1-ones
See Part - V, Section - I(C).
[D] Synthesis of 3-Cyano-6-(p-tolyl)-4-(1'N-phenyl-3'-β-pyridyl-4'-
pyrazolyl)-1,2-dihydropyridin-2-one
A mixture of 1-(p-Tolyl)-3-(1'N-phenyl-3'-β-pyridyl-4'-pyrazolyl)-2-propene-
1-one (3.65 g, 0.01 M), ethylcyanoacetate (1.13 g, 0.01 M) and anmmonium
acetate (5.92 g, 0.08 M) was fused for 2 hrs. diluted with ethanol, cooled, poured
into water and the crude product was isolated, crystallised  from ethanol. Yield
70%; m.p. 210oC. (Anal calcd. for C27H19N5O Found: C, 69.81; H, 3.99; N,
15.02; Required : C, 69.90; H, 3.91; N, 15.10%).
TLC solvent system: Acetone : Benzene (6 : 4)
Similarly other substituted pyridones have been prepared. The physical
data are recorded in Table No. 7.
[E] Synthesis of 3-Cyano-6-(p-tolyl)-4-(1'N-phenyl-3'-β-pyridyl-4'-
pyrazolyl)-1,2-dihydropyridin-2-one
Antimicrobial testing was carried out as described in Part - I, Section -
























7a C6H5- C26H17N5O 415 133 0.518 68 16.86 16.71
7b 4-F-C6H4- C26H16N5OF 433 158 0.748 51 16.16 16.02
7c 4-Cl-C6H4- C26H16N5OCl 449.5 163 0.612 64 15.57 15.41
7d 4-NH2-C6H4- C26H18N6O 430 128 0.648 55 19.52 19.40
7e 4-NO2-C6H4- C26H16N6O3 460 219 0.632 39 18.25 18.09
7f 3-NO2-C6H4- C26H16N6O3 460 238 0.712 71 18.25 18.10
7g 4-OH-C6H4- C26H17N5O2 431 141 0.509 58 16.23 16.04
7h 2-OH-C6H4- C26H17N5O2 431 102 0.679 84 16.23 16.09
7i 4-OCH3-C6H4- C27H17N5O2 445 90 0.524 73 15.72 15.58
7j 4-CH3-C6H4- C27H19N5O 429 120 0.651 70 15.10 15.02
7k 4-Br-C6H4- C26H16N5OBr 494 148 0.619 65 14.17 14.01
7l C5H4N- C25H16N6O 416 198 0.591 61 20.18 20.02


































B. mega 18 20 14 21 18 16 13 15 21 20 14 12 22 24 23
S. aureus 12 15 19 20 13 11 15 16 17 12 14 13 20 22 19
E. coli 18 13 14 13 17 20 11 12 14 15 14 13 19 18 20
P. vulgaris 13 18 13 14 12 14 16 16 13 12 17 14 17 20 21
A.niger 18 17 18 20 21 17 18 14 15 16 14 14 0 0 0









Amongst nitrogen containing five membered heterocycles, pyrazolines
have proved to be the most useful framework for biological activities. Pyrazolines
have attracted attention of medicinal chemists for both with regard to heterocyclic
chemistry and the pharmacological activity associated with them. The chemistry
of pyrazoline was reviewed by Jarboe in 1967, which have been studied
extensively for their biodynamic behaviour332 and industrial applications333.
Pyrazoline has three possible tutomeric structures, but the structure shown is
the most stable, which can be prepared from hydrazine hydrate and acrolein.
SYNTHETIC ASPECTS
Different methods for the preparat ion of 2-pyrazol ine derivat ives
documented in literature are as under :
1. The most common procedure for the reaction of an aliphatic or aromatic
hydrazine with α-β-unsaturated carbonyl compounds.




























3. 2-Pyrazoline derivatives can be prepared by intramolecular 1,3-dipolar
addition of diarylnitrilimines generated from 2,5-diaryltetrazoles334.
4. Epoxidation of chalcones gave epoxy ketones which reacted with hydrazine
and phenyl hydrazine to give pyrazolines335.
5. 2-Pyrazoline can be constructed by the cyclocondensation of chalcones
with hydrazine hydrate336.
6. Dipolar cycloaddition of nitrilimines of dimethyl fumarate, fumaronitrile
and the N-aryl maleimides yields the corresponding pyrazolines337.
7. 2-Pyrazoline can be prepared by condensation of chalcone dibromide with
hydrazines338.
One pot synthesis of some pyrazolines in dry media under microwave
irradiation is investigated by B. Gyassi et. al.339 Further more S. Paul et.
al.340and Dandia Anshu341 have also described the microwave assisted
synthesis of 2-pyrazolines.
REACTION MECHANISM
The following mechanism seems to be operable for the condensation of










( i ) proton transfer





















Nucleophilic attack by hydrazine at the β-carbon of the α-β-unsaturated
carbonyl system forms species (II), in which the -ve charge is mainly accomodated
by the electronegative oxygen atom. Proton transfer from the nitrogen to -ve
oxygen produces an intermediate enol which simultaneously ketonises to
ketoamine.
Another intermolecular nucleophillic attack by the primary amino group
of ketoamine on its carbonyl carbon followed by proton transfer from nitrogen
to oxygen leads ultimately to carbonyl amine. The later with a hydroxy group
and amino group on the same carbon loss water easily to yield the pyrazolines.
THERAPEUTIC IMPORTANCE














F.Manna and co-workers355 have described 1H-pyrazolines and its
derivatives as potent antiinflammatory, analgesic and antipyratic agents. Nugent
Richard et. al.356 have investigated pyrazolines bis phosphonate as novel
antiinflammatory and antiarthritic agents. Tuntawy, Atif et. al.357 have patented
pyrazolines as antibacterial agents.
115Pyrazolines...
G.  Mishirika et. al.358 have also prepared 2-pyrazoline derivatives of
salicyclic acid possessing antimicrobial properties. Udupi R. and Bhat A. 359
have reported the synthesis and biological activity of Mannich bases of certain
1,2-pyrazolines. T. Stivenson et. al.260 have also investigated N-substituted
pyrazoline as insecticidal agent.
B. Shivarama Holla et. al.261 have synthesised pyrazolines (I) and tested
them as antibacterial agents. Nisha Singh and co-workers362 have synthesised
1-acetyl pyrazolines (II) and reported them as potent pesticides and fungicides.
Heetika Malik et. al.363 have prepared 1H-pyrazoline derivatives and
reported them as pesticides. E. Palska et. al.364 have prepared 3,5-diphenyl-2-
pyrazoline derivatives (IV) and screened them as antidepressant agents. Shulabh
Sharma et. al.365 have synthesised some pyrazoline derivatives (V) of anthranilic















CONTRIBUTION FROM OUR LABORATORY
Jatin Upadhyay et. al.366 have synthesised 1-acetyl-4,5-dihydro-5-(4-
hydroxy-3-methoxyphenyl)-3-(4-phenylsulphonamidophenyl)-1H-pyrazoline and
other derivatives for their antimicrobial activity. Vikani and co-workers367 have
synthesised pyrazoline derivatives from arsanilic acid for their antimicrobial
activity against different strains of bacteria and fungi. P. Patel et. al.368 have
reported some novel pyrazoline derivatives as antimicrobial agents. Patel and
Parikh369 have investigated 3-(3'-Bromo-4'-acetamidophenyl)0-5-aryl-1H/1-
acetyl-2-pyrazolines. Bhatt and Parekh et. al.370 have shown moderate
antimicrobial activity of some pyrazoline derivatives. N. S. Shah and A. R. Parikh
et. al.371 have synthesised pyrazolines and reported them as potent antimicrobial
agents. Fatema Bharmal et. al.372 have shown good biological activity of
pyrazolines.
Recently Z. Brozowski et. al.373 have synthesised some pyrazolines and
reported them as antitumor agents. Malhotra et. al.374 have investigated
pyrazolines as cardiovascular agents. Maurer Fritz and co-workers375 have
synthesised pyrazolines used as pesticidal coating material agents. Shrinivas et.
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The significant biological properties associated with pyrazolines have
aroused considerable interest to design the compounds in which therapeutically
active pyrazole nucleus is incorporated with a view to obtaining compounds
with better drug potential and to study their pharmacological profile, which
have been described as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1 - A R Y L - 5 - ( 1 ' N - P H E N Y L - 3 - β - P Y R I D Y L - 4 ' -
PYRAZOLYL)-PYRAZOLINES





SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-5-(1'N-
PHENYL-3-β-PYRIDYL-4'-PYRAZOLYL)-PYRAZOLINES
Pyrazoline derivatives are endowed with valid antimicrobial activities.
Looking at their versatile therapeutic importance and with an aim to getting
better drug, it was considered worthwhile to synthesise some new pyrazolines.
The preparation of 1-aryl-5-(1'N-phenyl-3-β-pyridyl-4'-pyrazolyl)-pyrazolines
(VIII) has been undertaken by cyclocondensation of chalcones of type (VI) with
hydrazine hydrate, as shown in reaction scheme.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared














IR SPECTRAL STUDY OF 1-(p-TOLYL)-5-(1'N-PHENYL-3-β-PYRIDYL-4'-PYRAZOLYL)-
PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2923 2975-2950 537
-CH3 C-H str. (sym.) 2850 2880-2860 "
C-H i. p. def. 1442 1470-1435 "
C-H o. o. p. def. 1396 1390-1370 "
Aromatic C-H str. 3050 3080-3030 538
C=C str. 1512 1520-1480 "
C-H i.p. def. 1026 1070-1020 "
C-H o.o.p. def. 835 835-810 "
Pyrazoline N-H str. 3330 3300-3200 540
C=N str. 1622 1650-1580 "
C-N str. 1176 1220-1020 "
Pyrazole C=N str. 1573 1650-1580 542
moiety C=C str. 1479 1540-1440 "
















































PMR SPECTRAL STUDY OF 1-(p-ANISYL)-5-(1 'N-PHENYL-3-β -PYRIDYL-4 ' -
PYRAZOLYL)-PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1. 3.03 Jmo=15.0 1H d. doublet -CHm
Jmn=9.0
2. 3.48 Jno=15.0 1H " -CHn
Jnm=9.0
3. 3.83 - 3H singlet Ar-OCH3
4. 5.09 Jon=15.0 1H d. doublet -CHo
Jom=15.0
5. 6.92 Jba=8.0 2H doublet Ar-Hb,b'
6. 7.37 - 4H multiplet Ar-Hc,d,f,g
7. 7.60 - 2H doublet Ar-Hj,l
8. 7.72 Jab=8.0 2H " Ar-Ha,a'
9. 7.95 - 2H multiplet Ar-Hh ; Ar-He
10. 8.63 - 1H singlet Ar-Hk



























SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-5-(1'N-
PHENYL-3-β-PYRIDYL-4'-PYRAZOLYL)-PYRAZOLINES
[A] Synthesis of N-Aminophenyl-α-methyl-α-(β-pyridyl) azomethine
See Part - V, Section - I(A).
[B] Synthesis of 1-Phenyl-3-(β-pyridyl)-4-formyl pyrazoles
See Part - V, Section - I(B).
[C] Synthesis of 1-(p-tolyl)-3-(1'N-phenyl-3'-β-pyridyl-4'-pyrazolyl)-2-
propene-1-ones
See Part - V, Section - I(C).
[D] Synthesis of 1-(p-anisyl)-5-(1'N-phenyl-3'-β-pyridyl-4'-pyrazolyl)-
pyrazolines
A mixture of 1-(p-anisyl)-3-(1'N-phenyl-3'-β-pyridyl-4'-pyrazolyl)-2-
propene-1-one (3.81 g, 0.01 M), hydrazine hydrate (2 ml, 0.04 M) in 30 ml
methanol was refluxed for 10 hrs. The solution was poured into crushed ice.
Product was isolated and crystallised from DMF. Yield 60%; m.p. 148oC. (Anal
calcd. for C24H21N5O Found: C, 72.75; H, 5.45; N, 17.61; Required : C, 72.89;
H, 5.35; N, 17.71%).
TLC solvent system: Acetone : Benzene (8 : 2)
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Table No. 8.
[E] Synthesis of 1-Aryl-5-(1'N-phenyl-3'-β-pyridyl-4'-pyrazolyl)-
pyrazolines
Antimicrobial testing was carried out as described in Part - I, Section -























8a C6H5- C23H19N5 365 158 0.618 58 19.16 19.01
8b 4-F-C6H4- C23H18N5F 383 160 0.579 72 18.27 18.11
8c 4-Cl-C6H4- C23H19N5Cl 399.5 192 0.671 64 17.51 17.38
8d 4-NH2-C6H4- C23H20N6 380 218 0.648 48 22.09 21.91
8e 4-NO2-C6H4- C23H18N6O2 410 202 0.650 55 20.48 20.31
8f 3-NO2-C6H4- C23H18N6O2 410 208 0.712 51 20.48 20.34
8g 4-Oh-C6H4- C23H19N5O 381 148 0.748 61 18.36 18.21
8h 2-Oh-C6H4- C23H19N5O 381 142 0.545 79 18.36 18.18
8i 4-OCH3-C6H4- C24H21N5O 395 148 0.678 60 17.71 17.61
8j 4-CH3-C6H4- C24H21N5 379 172 0.512 82 18.46 18.28
8k 4-Br-C6H4- C23H18N5Br 444 137 0.591 57 15.76 15.59
8l C5H4N- C22H18N6 366 198 0.540 66 22.94 22.78


































B. mega 13 18 19 19 18 16 18 21 11 14 15 14 22 24 23
S. aureus 13 12 14 15 11 17 19 18 14 17 15 14 20 22 19
E. coli 15 11 16 18 17 14 19 18 17 14 14 12 19 18 20
P. vulgaris 12 16 11 13 12 16 20 13 15 15 14 13 17 20 21
A.niger 13 16 14 19 18 21 17 16 20 18 14 15 0 0 0






SYNTHESIS AND THERAPEUTIC EVALUATION OF 1N-ACETYL-3-
ARYL-5-(1'N-PHENYL-3-β-PYRIDYL-4'-PYRAZOLYL)-PYRAZOLINES
With a view to getting better biologically active compounds and considering
the association of various pharmacological activity of pyrazoles the preparation
of 1N-acetyl-3-aryl-5-(1'N-phenyl-3-β-pyridyl-4'-pyrazolyl)-pyrazolines (IX) have
been undertaken by the condensation of different chalcones of type (VI) with
hydrazine hydrate in presence of glacial acetic acid as a solvent, as shown in
reaction scheme.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared















R = ArylType - (IX)
126
IR SPECTRAL STUDY OF 1N-ACETYL-3-(p-TOLYL)-5-(1'N-PHENYL-3-β-PYRIDYL-4'-
PYRAZOLYL)-PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2916 2975-1950 537
-CH3 C-H str. (sym.) 2852 2880-2860 "
C-H i. p. def. 1425 1470-1435 "
C-H o. o. p. def. 1373 1390-1370 "
Aromatic C-H str. 3051 3080-3030 538
C=C str. 1558 1520-1480 "
C-H i.p. def. 1045 1070-1000 "
C-H o.o.p. def. 813 835-810 "
Pyrazoline C=O str. 1662 1660-1600 540
C=N str. 1602 1650-1580 "
C-N str. 1182 1220-1020 "
Pyrazole C=N str. 1639 1650-1580 542
moiety C=C str. 1471 1540-1440 "





























































PMR SPECTRAL STUDY OF 1N-ACETYL-3-(p-ANISYL)-5-(1'N-PHENYL-3-β-PYRIDYL-
4'-PYRAZOLYL)-PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1. 2.43 - 3H singlet -COCH3
2. 3.09 Jnm=9.0 1H d. doublet -CHn
Jno=15.0
3. 3.69 Jmn=9.0 1H " -CHm
Jmo=15.0
4. 3.84 - 1H singlet Ar-OCH3
5. 5.79 Jon=18.0 1H d. doublet -CHo
Jom=12.0
6. 6.92 Jgf=8.0 2H doublet Ar-Hg,g'
7. 7.27 - 1H multiplet Ar-Hd
8. 7.42 - 3H " Ar-Hc,e,k
9. 7.65 - 4H " Ar-Hf,f'
Ar-Ha; Ar-Hb
10. 7.82 - 1H singlet Ar-Hh
11. 6.27 - 1H doublet Ar-Hl
12. 8.61 - 1H " Ar-Hj



































IR SPECTRAL DATA OF 1N-ACETYL-3-ARYL-5-(1'N-PHENYL-3-β-PYRIDYL-4'-
PYRAZOLYL)-PYRAZOLINES




































































BASE PEAKm/z = 485 (m -1 )
m/z = 155 
m/z = 135 
m/z =  410 
m/z =  244
m/z =  174
m/z =  442 
m/z =
m/z =  267 
131
EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1N-ACETYL-3-
ARYL-5-(1'N-PHENYL-3-β-PYRIDYL-4'-PYRAZOLYL)-PYRAZOLINES
[A] Synthesis of N-Aminophenyl-α-methyl-α-(β-pyridyl) azomethine
See Part - V, Section - I(A).
[B] Synthesis of 1-Phenyl-3-(β-pyridyl)-4-formyl pyrazoles
See Part - V, Section - I(B).
[C] Synthesis of 1-(p-tolyl)-3-(1'N-phenyl-3'-β-pyridyl-4'-pyrazolyl)-2-
propene-1-ones
See Part - V, Section - I(C).
[D] Synthesis of 1N-Acetyl-3-(p-anisyl)-5-(1'N-phenyl-3'-β-pyridyl-4'-
pyrazolyl)-pyrazolines
A mixture of 1-(p-anisyl)-3-(1'N-phenyl-3'-β-pyridyl-4'-pyrazolyl)-2-
propene-1-one (3.81 g, 0.01 M), hydrazine hydrate (2 ml, 0.04 M) in 30 ml
glacial acetic acid was refluxed for 10 hrs. The solution was poured into crushed
ice. Product was isolated and crystallised from DMF. Yield 55%; m.p. 220oC.
(Anal calcd. for C26H23N5O2 Found: C, 66.05; H, 4.84; N, 16.18; Required :
C, 66.17; H, 4.70; N, 16.29%).
TLC solvent system: Acetone : Benzene (7.5 : 2.5)
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Table No. 9.
[E] Synthesis of 1N-Acetyl-3-aryl-5-(1'N-phenyl-3' -β-pyridyl-4' -
pyrazolyl)-pyrazolines
Antimicrobial testing was carried out as described in Part - I, Section -
























9a C6H5- C25H21N5O 407 110 0.628 59 17.19 17.03
9b 4-F-C6H4- C25H20N5OF 425 210 0.692 48 16.46 16.32
9c 4-Cl-C6H4- C25H20N5OCl 441.5 216 0.641 52 15.85 15.72
9d 4-NH2-C6H4- C25H22N6O 422 198 0.708 60 19.89 19.71
9e 4-NO2-C6H4- C25H20N6O3 452 208 0.648 44 18.57 18.40
9f 3-NO2-C6H4- C25H20N6O3 452 148 0.542 49 18.57 18.38
9g 4-OH-C6H4- C25H21N5O2 423 132 0.578 71 16.54 16.39
9h 2-OH-C6H4- C25H21N5O2 423 124 0.638 78 16.54 16.41
9i 4-OCH3-C6H4- C26H23N5O2 437 220 0.549 55 16.29 16.18
9j 4-CH3-C6H4- C26H23N5O 421 188 0.689 59 16.01 15.84
9k 4-Br-C6H4- C25H20N5OBr 486 198 0.641 48 14.40 14.23
9l C5H4N- C24H20N6O 408 178 0.508 52 20.58 20.44


































B. mega 15 16 19 17 17 20 14 19 11 17 21 14 22 24 23
S. aureus 15 14 14 15 11 12 15 13 16 17 14 17 20 22 19
E. coli 19 13 15 14 15 17 15 16 13 11 13 16 19 18 20
P. vulgaris 14 11 13 13 12 14 13 16 14 15 14 13 17 20 21
A.niger 14 14 21 15 13 18 20 17 16 17 18 14 0 0 0









Pyridine is the parent compound which is important in pharmaceutical,
agriculture and industrial applications. Pyridine derivatives acquire a special
position due to their wide range of biological activities. Pyridine is found in
coal tar. However, the simple pyridine compounds are prepared by the cyclisation
of aliphatic raw materials.
Pyridine is classified as aromatic on the basis of its properties. It is a flat,
with bond angles of 120o, the four carbon-carbon bonds are of the same length,
and so are the two carbon-nitrogen bonds. It resists addition and undergoes
electrophillic substitution. Its heat of combustion indicates a resonance energy
of 23 Kcal/mol. Pyridine can be considered a hybrid of the Kekule structures I
and II. We shall represent it as structure III, in which the circle represents the
aromatic sextet.
Pyridine contribute as an important class of compounds in medicinal
chemistry, leading to several new drugs currently used especially as calcium
channel antagonist377.
SYNTHETIC ASPECTS
A considerable variety of methods are available for the preparation of
pyridines.
a. Dornow and Neuse378 synthesised substituted pyridines by boiling
ethylcyanoacetate and ethylacetoacetate with ammonia.
b. Substituted pyridines can be prepared by the vapour phase air oxidation
of nicotine over V2O5




c. Anderson and co-workers381 prepared substituted pyridine by the addition
to nitrile to perfluoro-1,3-cyclohexadiene.
d. Goshaev, M. et. al.382 prepared bipyridine with the help of Ullmann
reaction.
e. Substituted pyridines can be prepared by the condensation of aldehyde
(R-CHO) with malononitrile in presence of alcoholic alkoxide (R'ONO)383.
f. Kusunoki and co-workers384 synthesised substituted pyridines by heating
paraldehyde with <C5 aliphatic primary or secondary amine at 200-300
oC
under high pressure in presence of catalyst.
g. A. Samour and co-workers385 prepared substituted pyridines by the
condensation of chalcones with malononitrile in presence of ammonium
acetate.
h. Pyridine is prepared by passing a mixture of acrolein, NH3 and O2 in the
vapour phase and at elexated temperature, over a catalyst of SiO2/Al2O3
impregnated with boron phosphate386.
i. Hantzsch synthesis is very wellknown method to prepared substituted
pyridines. It consists of condensing two molecules of β-diketones, aldehyde
and ammonia. The process comparises aldol condensation, enamines
















































Several pyridine derivatives reported to possess pharmacological activity





































































Literature survery revealed that various pyridines have resulted in many
















Lansaprazole, substituted pyridine derivatives (IV) has been described as
gastric (ulcer) acid secretion inhibitor. It has in vitro antimicrobial activity against
Helicobacter Pylori402,403.
The insecticidal activity of pyridines has been screened by Y. Sasaki et.
al.404. Umed ten et. al.405 have prepared pyridine derivatives as agrochemical
fungicides. The oxide activator bleaching activity of pyridine has been proved
by Rees M.406 Gangjee and et. al.407 have synthesised some novel pyridine
derivatives as potent antitumor agents. Oshida Mario408 prepared pyridine
derivatives which inhibit cerebral edema and delayed neuron death. Hence,











Several co-workers have prepared some novel pyridine derivatives and
reported their cholinesterase inhibitors409, antihistaminic and antiallergic410,
adernegic411, herbicidal412, antiinflammatory413 and insecticidal414 activities.
El-Nabawia et. al.415 have synthesised new 2-aminopyridine derivatives and
studied their antimicrobial activity. Hammama A. and co-workers416 have
prepared some new pyridine derivatives showing anticancer and antiHIV-1
activity. Abdallah N. et. al.417 have prepared pyridine derivatives which showed
analgesic and antiinflammatory activity.
Owa, Takashi and co-workers418 have prepared some new pyridine
derivatives (V) and reported their antitumor agents. Cao and et. al.419 have
synthesised some novel pyridine derivatives (VI) as insecticidal agents.
Van Wagenen et. al.420 have prepared some new pyridine derivatives (VII)
which is useful as metabotropic glatamate receptor antagonists for inhibiting
neuronal damage. Atkinson R. N. and Gross M. F.421 prepared pyridine


























The universal template approach to drug design foresses that pyridines
can modified in such a way to achieve better therapeutic agents, we have
synthesised pyrimidines, thio-pyrimidinones and aminopyrimidines bearing
pyridine nucleus. These study is described in following parts,
[B] STUDIES ON PYRIDINES
PART - I : STUDIES ON OXOPYRIMIDINES
PART - II : STUDIES ON THIOPYRIMIDINONES
PART - III : STUDIES ON AMINOPYRIMIDINES
140Pyridines...




Pyrimidine derivatives like uracil (I), thymine (II) and cytosin (III) occur
widely in nature showing remarkable pharmaceutical importance because of
their diverse biological activities. Several analogs of nucleic acids have been
used as compounds that interfere with the synthesis and functioning of nucleic
acids, an example is fluorouacil which has been used in cancer treatment.
Pyrimidine ring carrying various substituents may be built up from two or
three aliphatic fragments by the principal synthesis or by a variety of other
synthesis which are complimentary rather than alternative to it. Despite
considerable localisation of π-electrons, at the nitrogen atom of oxopyrimidine,
the ring system is still sufficiently aromatic to possess substantial stability. The
first primary synthesis from aliphatic fragments was carried out by Frankland
and Kolbe's in 1948.
SYNTHETIC ASPECTS
Popular methods for the preparation of oxopyrimidine derivatives have
been reported by synthesis from acyclic precursors, which have been described
under the following synthesis.
1. Takai Haruki and  co-workers422 have prepared oxopyrimidine derivatives


















2. Hussain Ali Saleiman et. al.423 have prepared oxopyrimidine derivatives
(V) by using urea in alcoholic KOH.
MECHANISM
































































Pyrimidinone derivatives have proven to be of great impor tance in












J. Lewis440 have studied oxo-pyrimidines and found to be active as
bactericidal and antiviral. Gardee V.441 have assessed oxo-pyrimidines against
the inhibition of serine protease. Bell Ian M. et. al.442 and Pierce et. al.443
have prepared oxo-pyrimidine derivatives which possess antagonists and HIV
reverse transcriptase activities. H. Junek and co-workers444 have prepared
pyrimidinones (VI) which were found to possess antiviral activity.
Mcguigan C. et. al.445 have evaluated oxopyrimidines (VII)  showing











Drewes et. al.447 have evaluated pyrimidinones as herbicidal and K.
Mogilaiah448 have reported spiropyrimidinones as antibacterial agent. M. B.
Deshmukh and co-workers449 have demonstrated some new pyrimidinone
derivatives and tested as biologically active agents. Anticancer activity of
oxopyrimidine derivatives have been reported by Kojima Eiji and co-workers450.
Recently, Michael et al.451 have prepared some new oxo-pyrimidine
derivatives and reported their herbicidal activity. In other study, Hastmat et.
al.452 have shown oxo-pyrimidine derivative analogues as nitric oxide synthase
inhibitors. Fluery Maurcee et. al.453 have demonstrated substituted derivatives
as CNS depressant. They have been also found to be active against the treatment
of wide obesity454. Adams Jerryl et. al.455 have formulated some new
pyrimidinone derivatives as antiinflammatory agents. Schnell and co-workers456
have reported antihypertensive activity and Sillier Daniel et. al.457 have
observed some of the products possessing adrenergic receptor antagonist activity.
Baldev Kumar et. al.458 have prepared some new oxo-pyrimidine derivatives
(IX) and reported them as potent calcium channel blockers. Abd. El-Galil and
M.  Abdulla459 have synthesised some fused steroidal oxo-pyrimidine derivatives

















More recently, Amjad Ali et. al.460 have prepared novel oxo-pyrimidines
which showed antimicrobial activity.
Pyrimidinone derivatives have attracted considerable attention in view of
their great biological activity. Taking this into consideration, the synthesis of
some novel pyrimidinones has been designed which is described as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3-ARYL-1-[β-PYRIDYL]-2-PROPENE-1-ONES





















SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-1-[β-
PYRIDYL]-2-PROPENE-1-ONES
As a part of our drug discovery program, considerable evidence has been
accumulated to demonstrate the efficiency of chalcones in inducing variety of
therapeutic activities. Our interest in further exploration in such a class of
compounds as antibacterial agent led us to synthesise a series of chalcones of
type (X) by the condensation of 3-acetylpyridine with different aromatic
aldehydes in presence of NaOH as shown in reaction scheme.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in  Part-I Section-I (D).









IR SPECTRAL STUDY OF 3-(p-ANISYL)-1-(β-PYRIDYL)-2-PROPENE-1-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2923 2962-2853 537
-CH3 C-H str. (sym.) 2852 2880-2860 "
C-H i.p. def. 1446 1470-1435 "
C-H o.o.p. def. 1402 1395-1370 "
Aromatic C-H str. 3053 3090-3030 538
C=C str. 1475 1520-1480 "
C-H i.p.def. 1037 1070-1000 "
C-H o.o.p. def. 806 835-810 "
Ether C-O-C str. 1220 1275-1200 537
Chalcone C=O str. 1666 1760-1655 539
Pyridine C=N str. 1598 1600-1580 542

















































PMR SPECTRAL STUDY OF 3-(p-ANISYL)-1-(β-PYRIDYL)-2-PROPENE-1-ONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1. 3.84 - 3H singlet Ar-OCH3
2. 7.01 Jfe=9.0 2H doublet Ar-Hf,f'
3. 7.37 Jba=3.0 1H d.doublet Ar-Hb
Jbc=9.0
4. 7.62 Jhg=15.0 1H doublet Vin-Hh
5. 7.78 Jgh=18.0 1H " Vin-Hg
6. 7.93 - 2H multiplet Ar-Hc ; Ar-Hd
7. 8.05 Jef=9.0 2H doublet Ar-He,e'
































IR SPECTRAL DATA OF 3-ARYL-1-(β-PYRIDYL)-2-PROPENE-1-ONES
















SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-1-[β-
PYRIDYL]-2-PROPENE-1-ONES
[A] Synthesis of 3-(p-Anisyl)-1-(β-pyridyl)-2-propene-1-one
A solution of 4-methoxybenzaldehyde (1.35 g, 0.01 M) in minimum quantity
of ethanol (5 ml) was added to a mixture of 3-acetylpyridine (1.2 g, 0.01 M) in
ethanol (20 ml) and 40% NaOH was added to make it alkaline. The reaction
mixture was then stirred for 24 hrs. at room temperature. The product was
isolated and crystallised from ethanol. Yield 80%; m.p. 188oC. (Anal calcd. for
C15H13NO2 Found: C, 75.18; H, 5.50; N, 5.70; Required : C, 75.31; H, 5.43;
N, 5.85%).
TLC solvent system: Acetone : Benzene (9 : 1)
Similarly other chalcones were prepared. The physical constants are
recorded in Table No. 10.
[B] Therapeutic evaluation of 3-Aryl-1-[β-pyridyl]-2-propene-1-ones
Antimicrobial testing was carried out as described in Part - I, Section -























10a C6H5- C14H11NO 209 162 0.617 78 6.69 6.51
10b 4-OCH3-C6H4- C15H13NO2 239 188 0.638 80 5.85 5.70
10c 4-Cl-C6H4- C14H10NOCl 243.5 138 0.728 81 5.75 5.60
10d 3-NO2-C6H4- C14H10N2O3 254 106 0.625 72 11.02 10.88
10e 4-OH-C6H4- C14H11N1O2 225 180 0.560 75 6.22 6.08
10f 2-OH-C6H4- C14H11NO2 225 148 0.506 72 6.22 6.09
10g 2-NO2-C6H4- C14H10N2O3 254 156 0.704 79 11.02 10.91
10h 2-Cl-C6H4- C14H10NOCl 243.5 128 0.667 80 5.75 5.58
10i α-CH=CH-C6H5- C16H13NO 235 190 0.520 75 5.95 5.81
10j 4-OH-3-OCH3-C6H3- C15H13NO3 255 218 0.598 72 5.49 5.32
10k 3-OC6H5-C6H4- C20H15NO2 301 279 0.611 81 4.65 4.51
10l 3,4-(OCH3)2-C6H3- C16H15NO3 269 208 0.652 70 5.20 5.06
10m α-C4H3O- C12H9NO2 199 110 0.540 71 7.03 6.90
10n C14H9-(9-Anthraldehyde) C22H15NO 309 174 0.512 72 4.52 4.39

































B. mega 18 20 16 17 16 14 16 15 17 19 18 18 14 13 22 24 2
S. aureus 15 17 14 18 13 12 13 15 14 16 17 12 15 14 20 22 1
E. coli 18 16 14 13 14 12 13 12 13 14 15 17 14 17 19 18 2
P. vulgaris 17 15 18 13 19 15 12 13 13 15 14 15 17 14 17 20 2
A.niger 13 18 14 13 17 17 20 17 18 19 15 14 13 15 0 0 0






SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYL-6-β-
PYRIDYL-1,2-DIHDYROPYRIMIDIN-2-ONES
During the past years, considerable evidences have been accumulated to
demonst ra te  the  potent ia l  o f  oxo-pyr imid ines .  To fur ther  assess  the
pharmacological importance of such a class of compounds as antibacterial agent,
a series of oxo-pyrimidine derivatives of type (XI) have been prepared by
cyclisation of chalcones of type (X) with various aldehydes and urea in presence
of alc. KOH as a catalyst. The reaction scheme is given below.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared













R = ArylType - (XI)
154
IR SPECTRAL STUDY OF 4- (p -CHLOROPHENYL) -6 - β -PYRIDYL-1,2 -
DIHYDROYRIMIDIN-2-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Aromatic C-H str. 3066 3090-3030 538
C=C str. 1487 1520-1480 "
C-H i.p.def. 1031 1070-1000 "
C-H o.o.p. def. 827 835-810 "
Pyrimidinone N-H str. 3369 3450-3200 539
ring C=O str. 1689 1690-1630 "
C-N str. 1074 1220-1020 542
C=N str. 1000 1640-1580 "
Pyridine C=N str. 1654 1640-1580 "
moiety C-N str. 1209 1220-1020 537





















































PMR SPECTRAL STUDY OF 4-(p-ANISYL)-6-β-PYRIDYL-1,2-DIHYDROPYRIMIDIN-
2-ONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1. 4.03 - 3H singlet Ar-OCH3
2. 7.10 Jgf=9.3 2H doublet Ar-Hg,g'
3. 7.69 - 1H singlet Ar-H,e
4. 6.13 Jfg=9.0 2H doublet Ar-Hf,f'
5. 8.32 Jcb=9.0 1H d.doublet Ar-Hc
Jcd=3.0
6. 9.20 - 2H multiplet Ar-hb ; Ar-Ha
7. 9.77 - 1H singlet Ar-Hd


































IR SPECTRAL DATA OF 4-ARYL-6-β-PYRIDYL-1,2-DIHYDROPYRIMIDIN-2-ONES
















SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYL-6-β-
PYRIDYL-1,2-DIHDYROPYRIMIDIN-2-ONES
[A] Synthesis of 3-(p-Anisyl)-1-(β-pyridyl)-2-propene-1-one
See Part - VIII, Section - I(A).
[B] Synthesis of 4-(p-Anisyl)-6-β-pyridyl-1,2-dihydropyrimidin-2-ones
To a mixture of 3-(p-Anisyl)-1-(β-pyridyl)-2-propene-1-one )2.39 gm, 0.01
M), and urea (0.60 g, 0.01 M) in alc. KOH was added and refluxed for 6 hrs.
The contents were then poured onto crushed ice and neutralised with dil. HCl
solution. The product obtained was isolated, filtered and crystallised from
ethanol. Yield 40%; m.p. 124oC. (Anal calcd. for C16H13N3O2 Found: C, 68.18;
H, 5.49; N, 14.80; Required : C, 68.32; H, 5.33; N, 14.94%).
TLC solvent system: Hexane : Ethylacetate (8 : 2)
Similarly other oxopyrimidines were prepared. The physical constants are
recorded in Table No. 11.
[C] Therapeutic evaluation of 4-Aryl-6-β-pyridyl-1,2-dihydropyrimidin-
2-ones
Antimicrobial testing was carried out as described in Part - I, Section -























11a C6H5- C15H11N3O 249 152 0.682 45 16.72 16.60
11b 4-OCH3-C6H4- C16H13N3O2 279 124 0.702 40 14.94 14.80
11c 4-Cl-C6H4- C15H10N3OCl 283.5 110 0.585 48 14.71 14.58
11d 3-NO2-C6H4
- C15H12N4O3 294 180 0.595 43 18.91 18.81
11e 4-OH-C6H4- C15H10N3O2 265 170 0.670 51 15.72 15.60
11f 2-OH-C6H4- C15H10N3O2 265 192 0.640 58 15.72 15.59
11g 2-NO2-C6H4- C15H12N4O3 294 158 0.710 54 18.91 18.78
11h 2-Cl-C6H4- C15H10N3OCl 283.5 134 0.545 62 14.71 14.60
11i α-CH=CH-C6H5- C17H13N3O 275 216 0.618 50 15.15 15.03
11j 4-OH-3-OCH3-C6H3- C16H13N3O3 295 197 0.572 48 14.13 14.01
11k 3-OC6H5-C6H4- C21H15N3O2 341 237 0.718 42 12.24 12.11
11l 3,4-(OCH3)2-C6H3- C17H15N3O3 309 208 0.682 45 13.50 13.36
11m α-C4H3O- C13H9N3O2 239 188 0.579 44 11.96 11.81
11n C14H9-(9-Anthraldehyde) C23H15N3O 349 257 0.514 52 17.42 17.28

































B. mega 22 20 14 13 19 20 18 22 17 12 16 15 17 15 22 24 2
S. aureus 20 19 14 13 21 18 21 12 15 16 14 19 18 12 20 22 1
E. coli 17 16 14 13 17 16 18 19 14 12 15 16 15 18 19 18 2
P. vulgaris 19 14 14 15 13 16 19 17 16 14 13 12 16 13 17 20 2
A.niger 20 14 15 16 22 20 19 21 17 16 14 18 18 17 0 0 0









Thiopyrimidine derivatives are an important class of pharmaceutically
active compounds and theri chemistry was extensively studied and continues to
attract the  attention of synthetic chemists. The thiopyrimidine derivatives and
many heterocyclic compounds containing thiopyrimidine moiety are known to
have major pharmacological activities.
SYNTHETIC ASPECTS
First primary synthesis of thiopyrimidine derivatives from aliphatic
fragments was carried out by Frankland and Kolbs in 1848. Since then a many
distinct primary synthetic method have been devised4461-465.
Different method reported are as under.
1. 2-Mercaptopyrimidines can be synthesised by G. W. Anderson466 through
condensation of thiourea and substituted β-keto ester in presence of sodium
ethoxide.
2. By the condensation of β-aldehydro nitr i le with formamidine and
thiourea467.
3. By the condensation of β-dinitrile with thiourea and guanidines468.
4. By the condensation of β-keto ester with N-methyl thiourea469.
















Literature survry revealed that various thiopyridines have resulted in many
potential drugs and are known to exhibit a broad spectrum of biological activity
such as :
1. Antiinflammatory and analgesic471-473
2. Antileishmanial474-776
3. Anticancer and herbicidal477,478
4. Antineoplastic479,480





A. S. Noravyan et. al.488 synthesised some thiopyrimidine derivatives as
anticonvulsant agent. Hozien Z. et. al.489 studied thiopyrimidine derivatives
and evaluated them for their antifungal and antibacterial activity. Moreover,
Mohran M. et. al.490 assessed some thiopyrimidine derivatives (I) as antitumor
and antibacterial agent.
Erker T. et. al.491 have prepared thiopyrimidines which have been shown
to possess muscle relaxant activity. Breozowskii Z.492 found thiopyrimidine as
anti-HIV. Nakatsuka M. et. al.493 prepared thiopyrimidines active against
inflammation.
Leone M. et. al.494 have studied some thiopyrimidines showing antibiotic






thiopyrimidines associated with marked hypolipemics and hypoglycemic,
anticonvulsant activities respectively. Schiafella F. et. al.497 adn Shafiee A. et.
a l .498 prepared th iopyr imid ines  and eva luated for  ant i funga l  and
antiinflammatory activity respectively.
Abou El-Fotooh et. al.499 prepared thiopyrimidine derivatives (II) which
showed anticancer activity.
N. M. Saleh and co-workers500 have prepared pyrimidine derivatives (III)
and reported their pharmacological activity.
Burbuliene M. M. et. al.501 synthesised some pyrimidine derivatives and
repor ted them as antiinflammatory agent. Okamura and co-workers502
evaluated pyrimidine derivatives for their adenosine A3 receptor affinity agent.





















(IV) and reported them as antibaterial and antifungal agent.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF










SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYL-6-β-
PYRIDYL-DIHYDROPYRIDIN-2-THIONES
Considerable attention has been focussed on the development and synthesis
of 1,3-thiazine derivatives of type (XII ) for obtaining biologically potent
molecules which have been prepared by the cyclocondensation of  chalcones of
type (X) with thiourea in alc. KOH solution as depicted in reaction scheme below.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared














IR SPECTRAL STUDY OF 4-(p-ANISYL)-6-β-PYRIDYL-DIHYDROPYRIMIDIN-2-
THIONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (sym.) 2848 2880-2860 537
-CH3 C-H i. p. def. 1469 1470-1435 "
C-H o. o. p. def. 1350 1385-1370 "
Aromatic C-H str. 3072 3080-3030 538
C=C str. 1506 1520-1480 "
C-H i.p. def. 1026 1070-100 "
C-H o.o.p. def. 825 835-810 "
Ether C-O-C str. 1259 1275-1200 537
Thiopyrimidine N-H str. 3423 3450-3200 539
ring C=N str. 1598 1660-1580 542
C-N str. 1161 1220-1020 537
C=S str. 1105 1200-1050 542
Pyridine C=N str. 1606 1660-1580 "























































PMR SPECTRAL STUDY OF 4-(p-ANISYL)-6-β-PYRIDYL-DIHYDRO PYRIMIDIN-2-
THIONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1. 3.82 - 3H singlet Ar-OCH3
2. 5.26 - 1H " CHg
3. 6.93 Jfe=8.7 2H doublet Ar-Hf,f'
4. 7.28 Jef=8.7 2H " Ar-He,e'
5. 7.40 - 1H triplet Ar-Hc
6. 7.78 Jab=3.0 1H d.doublet Ar-Ha
Jab=9.0
7. 8.64 Jba=9.0 1H " Ar-Hb
Jbc=9.0


























SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYL-6-β-
PYRIDYL-DIHYDROPYRIDIN-2-THIONES
[A] Synthesis of 3-(p-Anisyl)-1-(β-pyridyl)-2-propene-1-one
See Part - VIII, Section - I(A).
[B] Synthesis of 4-(p-Anisyl)-6-β-pyridyl-dihydropyrimidin-2-thiones
To a mixture of 3-(p-Anisyl)-1-(β-pyridyl)-2-propene-1-one (2.39 gm, 0.01
M), and thiourea (0.76 g, 0.01 M) alc. KOH was added and refluxed for 6 hrs.
The contents were then poured onto crushed ice and neutralised with dil HCl
solution. The product obtained was isolated, filtered and crystallised from
ethanol. Yield 55%; m.p. 162oC. (Anal calcd. for C16H13N3O5 Found: C, 64.50;
H, 5.15; N, 14.02; Required : C, 64.64; H, 5.05; N, 14.14%).
TLC solvent system: Hexane : Ethylacetate (6 : 4)
Similarly other thiopyrimidines were prepared. The physical constants are
recorded in Table No. 12.
[C] Therapeutic evaluation of 4-Aryl-6-β-pyridyl-dihydropyrimidin-2-
thiones
Antimicrobial testing was carried out as described in Part - I, Section -






















12a C6H5- C15H11N3S 265 179 0.612 58 15.72 15.61
12b 4-OCH3-C6H4- C16H13N3OS 295 162 0.580 55 14.14 14.02
12c 4-Cl-C6H4- C15H10N3SCl 299.5 202 0.528 59 13.92 13.80
12d 3-NO2-C6H4- C15H10N4O2S 310 188 0.618 60 17.94 17.78
12e 4-OH-C6H4- C15H11N3OS 281 239 0.577 65 14.83 14.70
12f 2-OH-C6H4- C15H11N3OS 281 222 0.512 58 14.83 14.67
12g 2-NO2-C6H4- C15H10N4O2S 310 180 0.620 48 17.94 17.81
12h 2-Cl-C6H4- C15H10N3SCl 299.5 208 0.581 53 13.92 13.81
12i α-CH=CH-C6H5- C17H13N3S 291 168 0.617 64 14.32 14.19
12j 4-OH-3-OCH3-C6H3- C16H13N3O2S 311 172 0.511 47 13.41 13.29
12k 3-OC6H5-C6H4- C21H15N3OS 357 271 0.708 49 11.69 11.55
12l 3,4-(OCH3)2-C6H3- C17H15N3O2S 325 158 0.538 70 12.83 12.71
12m α-C4H3O- C13H9N3OS 255 163 0.522 53 16.33 16.21
12n C14H9-(9-Anthraldehyde) C23H15N3S 365 142 0.513 68 11.44 11.29

































B. mega 21 14 15 18 17 14 13 12 16 18 20 19 22 14 22 24 23
S. aureus 20 19 14 14 13 17 18 12 15 16 14 21 13 16 20 22 19
E. coli 19 14 13 17 16 15 12 14 15 12 17 18 17 14 19 18 20
P. vulgaris 17 14 16 14 12 14 16 12 13 15 18 16 19 13 17 20 21
A.niger 21 20 14 15 13 16 17 15 14 16 22 20 16 17 0 0 0









2-Aminopyrimidine is the most important member of all the diazines as
this ring system occurs widely in living organisms. Pyrimidine was first isolated
by Gabriel and Colman in 1899. 2-Aminopyrimidine and its derivatives represent
one of the most active class of compounds possesing a wide spectrum of biological
activities.
SYNTHETIC ASPECTS
1. Rasaki504 synthesised 2-aminopyrimidne by the reaction of chalcone
epoxides with guanidine carbonate in xylene.
2. The reaction of chalcone with guanidine hydrochloride in presence of
potass ium-t-butoxide in t -butanol yie lded corresponding 2-amino
pyrimidine derivatives505.
3. Abd-El-gail, E. Amr506 synthesised aminopyrimidines by the reaction of





Mechanism of formation of aminopyrimidines is illustrated as under507.
THERAPEUTIC IMPORTANCE




3. Inhibitor and proliferation511




8. Tyrosine Kinase Inhibitor516
9. Adrenaline α receptor blocker517
Large no. of drugs possess aminopyrimidine ring system. Well-known
antimalarial agents like trimethoprim (I) and pyrimethamine, hypotensive agent














































Hisaki Masakatsu518 synthesised some aminopyrimidines which are useful
in the treatment of rotaviral diseases. Robson C. et. al.519 prepared amino
pyrimidine derivatives as antifungal agents in P9P and MRP over expressive
tumor cell lines. Leanne M. et. al.520 have prepared aminopyrimidines and
repor ted them as  ant iv i ra l  agent .  Yamada K.521 synthes i sed some
aminopyrimidines (IV) and tested for endothelin antagonists.
Suto, M. et. al.522 prepared some aminopyrimidines which were found to
possess antiinflammatory, anticancer, antirheumatoid activities. Gangjee A. et.
al.523 synthesised aminopyrimidines which possess antitumor activity. Ugarkar

























Hernan dez et. al.525 and Secrist J. et. al.526 prepared aminopyrimidines
showing antitumor activity. Glazier A. et. al.527 and Singh J.528 found
aminopyrimidines as antiviral agents. Pan S.529 prepared 2-methylthio-4-amino-
6-(3,5-diacetylphenylamino) pyrimidines which show anti HIV activity in H9
cell cultures. Aminopyrimidine derivatives also possess antimicrobial530,
antiHIV531 and antitumor532 activities.
Bargiotti et. al.533 prepared aminopyrimidines (V) showing anticancer
activity. Gangjee Aleem534 synthesised some aminopyrimidines (VI) and tested
for dihydrofolate reductase inhibitors.
Jianming Zu. et. al.535 synthesised N-{4-[2-(2-amino-4-ethylpyrrolo-[2,3-
d] pyrimidin-5-yl)ethyl] benzoyl}-L-glumatic acid (VII) its 6-methyl derivative
as potential dual inhibitors of thymidylate synthesis and dihydrofolate reductase
and as potential antitumor agents. Tsutsumi et. al.536 have prepared some











































Looking to the diversified activities exhibited and in continuation of our
work on the synthesis of biologically active heterocycles, the synthesis and
biological screening of aminopyrimidine derivatives have ben described as under.









SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-AMINO-4-ARYL-
6-β-PYRIDYL-PYRIMIDINES
Many aminopyrimidine derivatives are reported to possess different
biological activities. In view of these reports, it was considered worthwhile to
synthesise some new 2-amino-4-aryl-6-β-pyridyl-pyrimidines of type (XIII) to
study their biological activities. Aminopyrimidine derivatives have been prepared
by the reaction of the chalcones of type (X) with guanidine hydrochloride in
presence of potassium-t-butoxide in t-butanol shown as under.
The constitution of the synthesised products has been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared














IR SPECTRAL STUDY OF 2-AMINO-4-(p-ANISYL)-6-β-PYRIDYL-PYRIMIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (sym.) 2852 2880-2860 537
-CH3 C-H i. p. def. 1467 1470-1435 "
C-H o. o. p. def. 1375 1385-1370 "
Aromatic C-H str. 3035 3080-3030 538
C=C str. 1514 1520-1480 "
C-H i.p.def. 1033 1070-1000 "
C-H o.o.p. def. 819 835-810 "
Ether C-O-C str. 1232 1275-1200 537
Aminopyrimi- N-H str. 3305 3450-3200 539
dine ring C=N str. 1596 1660-1580 542
C-N str. 1176 1220-1020 537
Pyridine C=N str. 1614 1660-1580 542




























































PMR SPECTRAL STUDY OF 2-AMINO-4-(p-ANISYL)-6-β-PYRIDYL-PYRIMIDINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1. 3.85 - 3H singlet Ar-OCH3
2. 5.26 - 2H " Ar-NH2
3. 7.02 Jgf=9.0 2H doublet Ar-Hg,g'
4. 7.41 Jbc=9.0 2H triplet Ar-Hb ; Ar-He
Jba=9.0
5. 8.05 Jfg=8.7 2H doublet Ar-Hf,f'
6. 8.35 Jca=3.0 1H d. doublet Ar-Hc
Jcb=8.7
7. 8.71 Jab=8.7 1H " Ar-Ha
Jac=3.0











































m/z = 280 (m + 2 )
m/z =  156
m/z =  233
m/z =  135
m/z =  149
m/z =  120
m/z =  208
m/z =  108
EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-AMINO-4-ARYL-
6-β-PYRIDYL-PYRIMIDINES
[A] Synthesis of 3-(p-Anisyl)-1-(β-pyridyl)-2-propene-1-one
See Part - VIII, Section - I(A).
[B] Synthesis of 2-Amino-4-(p-anisyl)-6-β-pyridyl-pyrimidine
A mixture of 3-(p-Anisyl)-1-(β-pyridyl)-2-propene-1-one (2.39 gm, 0.01
M)and guanidine hydrochloride (1.10 g, 0.01 M) was refluxed in potassium-t-
butoxide (1.12 g, 0.01 M) in t-butanol (20 ml) on a water-bath for 5 hrs. The
solvent was evaporated and the residue was neutralized with 20% HCl, the
separated solid was filtered out and crystallised from ethanol. Yield 50%; m.p.
192oC. (Anal calcd. for C16H14N4O Found: C, 68.70; H, 5.58; N, 19.90;
Required : C, 68.57; H, 5.71; N, 20.0%).
TLC solvent system: Hexane : Ethylacetate (5.5 : 4.5)
Similarly other aminopyrimidines were prepared. The physical constants
are recorded in Table No. 13.
[C] Therapeutic evaluation of 2-Amino-4-aryl-6-β-pyridyl-pyrimidines
Antimicrobial testing was carried out as described in Part - I, Section -






















13a C6H5- C15H12N4 248 142 0.658 51 22.38 22.31
13b 4-OCH3-C6H4- C16H14N4O 278 192 0.742 50 20.0 19.90
13c 4-Cl-C6H4- C15H11N4Cl 282.5 148 0.667 48 19.68 19.60
13d 3-NO2-C6H4- C15H11N5O2 293 180 0.560 51 23.72 23.62
13e 4-OH-C6H4- C15H12N4O 264 190 0.687 49 21.04 20.91
13f 2-OH-C6H4- C15H12N4O 264 212 0.565 52 21.04 20.94
13g 2-NO2-C6H4- C15H11N5O2 293 185 0.480 54 23.72 23.60
13h 2-Cl-C6H4- C15H11N4Cl 282.5 143 0.568 41 19.68 19.56
13i α-CH=CH=C6H5- C17H14N4 274 235 0.456 48 20.42 20.29
13j 4-OH-3-OCH3-C6H3- C16H14N4O2 294 160 0.753 50 18.91 18.80
13k 3-OC6H5-C6H4- C21H16N4O 340 165 0.684 48 16.36 16.22
13l 3,4-(OCH3)2-C6H3- C17H16N4O 308 220 0.676 49 18.05 17.92
13m α-C4H3O- C13H10N4O 238 251 0.580 47 23.32 23.20
13n C14H9-(9-Anthraldehyde) C23H16N4 348 280 0.588 43 15.99 15.84






























B. mega 20 14 17 20 15 17 12 13 22 19 11 20 18 14 22 24 2
S. aureus 14 19 12 19 20 12 16 20 13 16 17 11 16 18 20 22 1
E. coli 19 16 13 20 14 16 14 12 19 11 12 18 14 16 19 18 2
P. vulgaris 15 17 12 16 15 14 11 19 14 17 15 15 12 17 17 20 2
A.niger 19 17 18 21 14 14 18 19 13 17 19 13 19 17 0 0 0
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